Identification
NameDoxorubicin
Accession NumberDB00997  (APRD00185, DB05331, DB05847)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.

Structure
Thumb
Synonyms
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-hydroxydaunomycin
14-hydroxydaunorubicine
Doxorubicin
Doxorubicine
Doxorubicinum
Hydroxydaunorubicin
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Doxorubicin citrateAJQ2ZNG2WL 111266-55-8INEKNBHAPBIAFK-RUELKSSGSA-NDetails
Doxorubicin hydrochloride82F2G7BL4E 25316-40-9MWWSFMDVAYGXBV-BADIEKLNSA-NDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Adriamycin PFSSolution2 mgIntravenous; IntravesicalPfizer1995-12-31Not applicableCanada
Adriamycin RdfPowder, for solution150 mgIntravenousPfizer1996-12-312006-08-02Canada
Adriamycin RdfPowder, for solution10 mgIntravenousPfizer1996-12-312006-08-02Canada
Adriamycin RdfPowder, for solution50 mgIntravenousPfizer1995-12-312006-08-02Canada
Adriamycin Rdf Inj 10mg/vialPowder, for solution10 mgIntravenousCarlo Erba Farmitalia Spa1976-12-311996-09-10Canada
Adriamycin Rdf Inj 150mg/vialPowder, for solution150 mgIntravenousAdria Laboratories Of Canada Ltd.1988-12-311996-09-10Canada
Adriamycin Rdf Inj 50mg/vialPowder, for solution50 mgIntravenousCarlo Erba Farmitalia Spa1976-12-311996-09-10Canada
CaelyxInjection, solution, concentrate2 mg/mlIntravenousJanssen Cilag International Nv1996-06-21Not applicableEu
CaelyxInjection, solution, concentrate2 mg/mlIntravenousJanssen Cilag International Nv1996-06-21Not applicableEu
CaelyxInjection, solution, concentrate2 mg/mlIntravenousJanssen Cilag International Nv1996-06-21Not applicableEu
CaelyxSuspension2 mgIntravenousJanssen Pharmaceuticals1998-08-19Not applicableCanada
CaelyxInjection, solution, concentrate2 mg/mlIntravenousJanssen Cilag International Nv1996-06-21Not applicableEu
DoxilInjection, suspension, liposomal2 mg/mLIntravenousJanssen, Lp1995-11-17Not applicableUs
DoxorubicinSolution2 mgIntravenous; IntravesicalPfizer2014-05-21Not applicableCanada
Doxorubicin HCl for Inj. U.S.P. 10mg/vialPowder, for solution10 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1995-12-311998-08-13Canada
Doxorubicin HCl for Inj. U.S.P. 150mg/vialPowder, for solution150 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1995-12-311997-08-14Canada
Doxorubicin HCl for Inj. U.S.P. 50mg/vialPowder, for solution50 mgIntravenousDavid Bull Laboratories (Pty) Ltd.1995-12-311997-08-14Canada
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.1987-12-23Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2014-03-17Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.1987-12-23Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2013-03-05Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2013-03-17Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.1987-12-23Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2013-03-05Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.1987-12-23Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2014-03-17Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2013-03-05Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2014-03-17Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2013-03-05Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.1987-12-23Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2013-03-05Not applicableUs
Doxorubicin Hydrochloride for Injection, USPPowder, for solution50 mgIntravenousHospira, Inc.1997-07-30Not applicableCanada
Doxorubicin Hydrochloride for Injection, USPPowder, for solution150 mgIntravenousHospira, Inc.1997-05-08Not applicableCanada
Doxorubicin Hydrochloride for Injection, USPPowder, for solution10 mgIntravenousHospira, Inc.1998-03-12Not applicableCanada
Doxorubicin Hydrochloride InjectionSolution2 mgIntravenous; IntravesicalSandoz Canada Incorporated2015-04-10Not applicableCanada
Doxorubicin Hydrochloride InjectionSolution2 mgIntravenousNovopharm Limited1997-09-12Not applicableCanada
Doxorubicin Hydrochloride InjectionSolution2 mgIntravenous; IntravesicalOmega Laboratories LtdNot applicableNot applicableCanada
Doxorubicin Hydrochloride InjectionSolution2 mgIntravenous; IntravesicalTeva2014-02-27Not applicableCanada
Doxorubicin Hydrochloride Injection, USPSolution2 mgIntravenous; IntravesicalMylan Pharmaceuticals2015-01-08Not applicableCanada
Doxorubicin Hydrochloride liposomeInjection, suspension, liposomal2 mg/mLIntravenousJanssen, Lp2017-06-26Not applicableUs
Doxorubicin InjectionSolution2 mgIntravenous; IntravesicalAccord Healthcare Limited2014-12-16Not applicableCanada
MyocetInjection, powder, for solution50 mgIntravenousTeva B.V.2000-07-13Not applicableEu
MyocetInjectable, liposomal2 mgIntravenousSopherion Therapeutics2001-12-21Not applicableCanada
MyocetInjection, powder, for solution50 mgIntravenousTeva B.V.2000-07-13Not applicableEu
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AdriamycinInjection, solution2 mg/mLIntravenousWest Ward Pharmaceutical1996-05-01Not applicableUs
AdriamycinInjection, solution2 mg/mLIntravenousWest Ward Pharmaceutical1996-05-01Not applicableUs
AdriamycinInjection, solution2 mg/mLIntravenousWest Ward Pharmaceutical1996-05-01Not applicableUs
AdriamycinInjection, solution2 mg/mLIntravenousWest Ward Pharmaceutical1996-05-01Not applicableUs
DOXOrubicin HydrochlorideInjection200 mg/100mLIntravenousAmneal Agila, Llc2013-04-30Not applicableUs
Doxorubicin HydrochlorideInjectable, liposomal2 mg/mLIntravenousNorth Star Rx Llc2017-08-29Not applicableUs
Doxorubicin HydrochlorideInjection10 mg/5mLIntravenousMylan Institutional2012-02-14Not applicableUs
Doxorubicin HydrochlorideInjection, powder, lyophilized, for solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2011-10-29Not applicableUs
Doxorubicin HydrochlorideInjection, powder, lyophilized, for solution2 mg/mLIntravenousAmneal Biosciences2017-02-17Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousTeva Parenteral Medicines, Inc.1995-09-01Not applicableUs
Doxorubicin HydrochlorideInjection, powder, lyophilized, for solution2 mg/mLIntravenousAmneal Biosciences2017-02-17Not applicableUs
Doxorubicin HydrochlorideInjectable, liposomal2 mg/mLIntravenousDr Reddy's Laboratories2017-05-22Not applicableUs
DOXOrubicin HydrochlorideInjection, solution2 mg/mLIntravenousSun Pharmaceutical Industries Limited2012-02-20Not applicableUs
Doxorubicin HydrochlorideInjectable, liposomal2 mg/mLIntravenousSun Pharma Global FZE2013-02-05Not applicableUs
Doxorubicin HydrochlorideInjection200 mg/100mLIntravenousMylan Institutional2012-02-14Not applicableUs
DOXOrubicin HydrochlorideInjection20 mg/10mLIntravenousAmneal Agila, Llc2013-04-30Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousGland Pharma Limited2017-08-22Not applicableUs
DOXOrubicin HydrochlorideInjection10 mg/5mLIntravenousAmneal Agila, Llc2013-04-30Not applicableUs
Doxorubicin HydrochlorideInjectable, liposomal2 mg/mLIntravenousNorth Star Rx Llc2017-08-29Not applicableUs
Doxorubicin HydrochlorideInjection20 mg/10mLIntravenousMylan Institutional2012-02-14Not applicableUs
Doxorubicin HydrochlorideInjection, powder, lyophilized, for solution2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2011-10-29Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousFresenius Kabi2000-06-14Not applicableUs
Doxorubicin HydrochlorideInjection, powder, lyophilized, for solution2 mg/mLIntravenousMylan Institutional2011-10-29Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousTeva Parenteral Medicines, Inc.1995-09-01Not applicableUs
Doxorubicin HydrochlorideInjectable, liposomal2 mg/mLIntravenousDr Reddy's Laboratories2017-05-22Not applicableUs
DOXOrubicin HydrochlorideInjection50 mg/25mLIntravenousAmneal Agila, Llc2013-04-30Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousGland Pharma Limited2017-08-22Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousTeva Parenteral Medicines, Inc.1996-09-01Not applicableUs
Doxorubicin hydrochlorideInjection, solution2 mg/mLIntravenousActavis Pharma Company2014-11-01Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousFresenius Kabi2000-04-14Not applicableUs
DOXOrubicin HydrochlorideInjection, solution2 mg/mLIntravenousSun Pharmaceutical Industries Limited2012-02-20Not applicableUs
Doxorubicin HydrochlorideInjectable, liposomal2 mg/mLIntravenousSun Pharma Global FZE2013-02-05Not applicableUs
Doxorubicin HydrochlorideInjection50 mg/25mLIntravenousMylan Institutional2012-02-14Not applicableUs
Doxorubicin HydrochlorideInjection, powder, lyophilized, for solution2 mg/mLIntravenousMylan Institutional2011-10-29Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousSagent Pharmaceuticals2013-10-31Not applicableUs
Doxorubicin HydrochlorideInjection, solution2 mg/mLIntravenousGland Pharma Limited2017-08-22Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdriablastinaPfizer
AdriamycinPfizer
AdriblastinActavis
RubexNot Available
Brand mixturesNot Available
Categories
UNII80168379AG
CAS number23214-92-8
WeightAverage: 543.5193
Monoisotopic: 543.174060775
Chemical FormulaC27H29NO11
InChI KeyAOJJSUZBOXZQNB-TZSSRYMLSA-N
InChI
InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
IUPAC Name
(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
SMILES
COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[[email protected]](O)(C[[email protected]@H]3O[[email protected]]3C[[email protected]](N)[[email protected]](O)[[email protected]](C)O3)C(=O)CO)C(O)=C1C2=O
Pharmacology
Indication

Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.

Structured Indications
Pharmacodynamics

Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.

Mechanism of action

Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.

TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideyes
intercalation
Humannot applicabledetails
DNA topoisomerase 2-alphaProteinyes
inhibitor
HumanP11388 details
Nucleolar and coiled-body phosphoprotein 1ProteinunknownNot AvailableHumanQ14978 details
Related Articles
AbsorptionNot Available
Volume of distribution

The distributive half-life is 5 minutes, which suggests that doxorubicin is rapidly taken up by tissue. Steady state volume of distribution = 809 to 1214 L/m2

Protein binding

Doxorubicin and its major metabolite, doxorubicinol, is 74-76% bound to plasma protein. The extent to binding is independent of plasma concentration up to 1.1 mcg/mL. Doxorubicin does not cross the blood brain barrier.

Metabolism

Doxorubicin is capable of undergoing 3 metabolic routes: one-electron reduction, two-electron reduction, and deglycosidation. However, approximately half of the dose is eliminated from the body unchanged. Two electron reduction yields doxorubicinol, a secondary alcohol. This pathway is considered the primary metabolic pathway. The one electron reduction is facilitated by several oxidoreductases to form a doxirubicin-semiquinone radical. These enzymes include mitochondrial and cystolic NADPH dehydrogenates, xanthine oxidase, and nitric oxide synthases. Deglycosidation is a minor metabolic pathway (1-2% of the dose undergoes this pathway). The resultant metabolites are deoxyaglycone or hydroxyaglycone formed via reduction or hydrolysis respectively. Enzymes that may be involved with this pathway include xanthine oxidase, NADPH-cytochrome P450 reductase, and cytosolic NADPH dehydrogenase.

SubstrateEnzymesProduct
Doxorubicin
DoxorubicinolDetails
Doxorubicin
Doxorubicin-semiquinoneDetails
Doxorubicin
Doxorubicinol deoxaglyconeDetails
Doxorubicin
Not Available
Doxorubicine hydroxyaglyconeDetails
Doxorubicine hydroxyaglycone
Not Available
Doxirubicinol hydroxyaglyconeDetails
Route of elimination

40% of the dose appears in bile in 5 days. 5-12% of the drug and its metabolites appears in urine during the same time period. <3% of the dose recovered in urine was doxorubicinol.

Half life

Terminal half life = 20 - 48 hours.

Clearance
  • 324-809 mL/min/m2 [by metabolism and biliary excretion]
  • 1088 mL/min/m2 [Men]
  • 433 mL/min/m2 [Women]
  • 1540 mL/min/m2 [children greater than 2 years of age receiving administration of 10 to 75 mg/m2 doses]
  • 813 mL/min/m2 [infants younger than 2 years of age receiving administration of 10 to 75 mg/m2 doses]
Toxicity

LD50=21800 ug/kg (rat, subcutaneous)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Doxorubicin Metabolism PathwayDrug metabolismSMP00650
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Retinoic acid receptor gamma---(C;C) / (C;T)C>T ADR Directly StudiedPediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with doxorubicin. Details
Solute carrier family 28 member 3---(A;A) / (A;G)G > A ADR Directly StudiedPediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with doxorubicin. Details
UDP-glucuronosyltransferase 1-6UGT1A6*4(T;T) / (G;T)G > T ADR Directly StudiedPediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with doxorubicin. Details
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Doxorubicin can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Doxorubicin.Approved
AceclofenacAceclofenac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
AcetaminophenThe serum concentration of Doxorubicin can be increased when it is combined with Acetaminophen.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Doxorubicin.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Doxorubicin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
AfatinibThe serum concentration of Doxorubicin can be increased when it is combined with Afatinib.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Doxorubicin.Approved
AlbendazoleThe serum concentration of Doxorubicin can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Doxorubicin can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Doxorubicin can be increased when it is combined with Alectinib.Approved
Alendronic acidDoxorubicin may increase the hypocalcemic activities of Alendronic acid.Approved
AlfentanilThe serum concentration of Doxorubicin can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Doxorubicin.Approved, Investigational
AmantadineThe serum concentration of Doxorubicin can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Doxorubicin.Approved, Investigational
AmdinocillinThe serum concentration of Doxorubicin can be decreased when it is combined with Amdinocillin.Withdrawn
Aminohippuric acidThe serum concentration of Doxorubicin can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Doxorubicin can be increased when it is combined with Amiodarone.Approved, Investigational
AmiodaroneThe metabolism of Doxorubicin can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Doxorubicin can be increased when it is combined with Amitriptyline.Approved
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Doxorubicin.Approved
AmlodipineThe serum concentration of Doxorubicin can be increased when it is combined with Amlodipine.Approved
AmoxicillinThe serum concentration of Doxorubicin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Doxorubicin.Approved, Investigational
AmpicillinThe serum concentration of Doxorubicin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AmprenavirThe serum concentration of Doxorubicin can be increased when it is combined with Amprenavir.Approved
AmprenavirThe serum concentration of Doxorubicin can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Doxorubicin can be increased when it is combined with Amsacrine.Approved
AndrographolideHMPL-004 may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Doxorubicin.Approved
ApocyninAcetovanillone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
AprepitantThe serum concentration of Doxorubicin can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Doxorubicin.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Doxorubicin.Approved, Investigational
ArtemetherThe serum concentration of Doxorubicin can be increased when it is combined with Artemether.Approved
ArtemetherThe metabolism of Doxorubicin can be decreased when combined with Artemether.Approved
AstemizoleThe serum concentration of Doxorubicin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Doxorubicin can be increased when it is combined with Atazanavir.Approved, Investigational
AtazanavirThe metabolism of Doxorubicin can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Doxorubicin can be increased when it is combined with Atenolol.Approved
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Doxorubicin.Approved
AtomoxetineThe serum concentration of Doxorubicin can be increased when it is combined with Atomoxetine.Approved
AtomoxetineThe metabolism of Doxorubicin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Doxorubicin can be increased when it is combined with Atorvastatin.Approved
Atracurium besylateDoxorubicin may increase the respiratory depressant activities of Atracurium besylate.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Doxorubicin.Approved, Investigational
AzapropazoneAzapropazone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Withdrawn
AzelastineThe serum concentration of Doxorubicin can be increased when it is combined with Azelastine.Approved
AzelastineAzelastine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Doxorubicin can be decreased when it is combined with Azidocillin.Approved
AzithromycinThe serum concentration of Doxorubicin can be increased when it is combined with Azithromycin.Approved
AzlocillinThe serum concentration of Doxorubicin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Doxorubicin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Doxorubicin.Investigational
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Doxorubicin.Investigational
BenoxaprofenBenoxaprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Doxorubicin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzocaineThe serum concentration of Doxorubicin can be increased when it is combined with Benzocaine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Doxorubicin.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Doxorubicin.Approved
BenzylpenicillinThe serum concentration of Doxorubicin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Doxorubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BepridilThe serum concentration of Doxorubicin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Doxorubicin.Approved, Vet Approved
BetaxololThe serum concentration of Doxorubicin can be increased when it is combined with Betaxolol.Approved
BetaxololThe metabolism of Doxorubicin can be decreased when combined with Betaxolol.Approved
Betulinic AcidBetulinic Acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Doxorubicin.Approved, Investigational
BexaroteneThe serum concentration of Doxorubicin can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Doxorubicin can be increased when it is combined with Biperiden.Approved
BoceprevirThe serum concentration of Doxorubicin can be increased when it is combined with Boceprevir.Withdrawn
BoceprevirThe metabolism of Doxorubicin can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe serum concentration of Doxorubicin can be increased when it is combined with Bortezomib.Approved, Investigational
BortezomibThe metabolism of Doxorubicin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Doxorubicin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Doxorubicin.Approved
Botulinum Toxin Type ADoxorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BDoxorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Doxorubicin.Approved
BromfenacBromfenac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
BromocriptineThe serum concentration of Doxorubicin can be increased when it is combined with Bromocriptine.Approved, Investigational
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Doxorubicin.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Doxorubicin.Approved
BucillamineBucillamine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Doxorubicin.Approved
BuprenorphineThe serum concentration of Doxorubicin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Doxorubicin can be increased when it is combined with Bupropion.Approved
BuspironeThe serum concentration of Doxorubicin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Doxorubicin can be increased when it is combined with Cabazitaxel.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Doxorubicin.Approved
CaffeineThe serum concentration of Doxorubicin can be increased when it is combined with Caffeine.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Doxorubicin.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Doxorubicin.Experimental
CanagliflozinThe serum concentration of Doxorubicin can be increased when it is combined with Canagliflozin.Approved
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Doxorubicin.Approved
CandesartanThe serum concentration of Doxorubicin can be increased when it is combined with Candesartan.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Doxorubicin.Approved
CaptoprilThe serum concentration of Doxorubicin can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Doxorubicin can be increased when it is combined with Carbamazepine.Approved, Investigational
CarbamazepineThe metabolism of Doxorubicin can be increased when combined with Carbamazepine.Approved, Investigational
CarbenicillinThe serum concentration of Doxorubicin can be decreased when it is combined with Carbenicillin.Approved
Carbenicillin indanylThe serum concentration of Doxorubicin can be decreased when it is combined with Carindacillin.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Doxorubicin.Approved
CarboplatinDoxorubicin may increase the ototoxic activities of Carboplatin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Doxorubicin.Approved
CarprofenCarprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Doxorubicin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Doxorubicin can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Experimental
CelecoxibThe serum concentration of Doxorubicin can be increased when it is combined with Celecoxib.Approved, Investigational
CelecoxibCelecoxib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
CeritinibThe serum concentration of Doxorubicin can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Doxorubicin.Withdrawn
ChloroquineThe serum concentration of Doxorubicin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChloroquineChloroquine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Vet Approved
ChlorpromazineThe serum concentration of Doxorubicin can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Doxorubicin.Approved, Vet Approved
ChlorpropamideThe serum concentration of Doxorubicin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Doxorubicin can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe serum concentration of Doxorubicin can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
CholecalciferolThe metabolism of Doxorubicin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Doxorubicin can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Doxorubicin can be decreased when it is combined with Cholic Acid.Approved
Choline magnesium trisalicylateTrisalicylate-choline may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
CilazaprilThe serum concentration of Doxorubicin can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Doxorubicin can be increased when it is combined with Cimetidine.Approved
CimetidineThe serum concentration of Doxorubicin can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of Doxorubicin can be increased when it is combined with Cinacalcet.Approved
CinacalcetThe metabolism of Doxorubicin can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Doxorubicin.Approved
CiprofloxacinThe serum concentration of Doxorubicin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Doxorubicin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Doxorubicin.Approved, Investigational, Withdrawn
Cisatracurium besylateDoxorubicin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Doxorubicin.Approved
CitalopramThe serum concentration of Doxorubicin can be increased when it is combined with Citalopram.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Doxorubicin.Approved
ClarithromycinThe serum concentration of Doxorubicin can be increased when it is combined with Clarithromycin.Approved
ClarithromycinThe metabolism of Doxorubicin can be decreased when combined with Clarithromycin.Approved
ClemastineThe serum concentration of Doxorubicin can be increased when it is combined with Clemastine.Approved
ClemastineThe metabolism of Doxorubicin can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Doxorubicin can be increased when it is combined with Clobazam.Approved, Illicit
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Doxorubicin.Approved, Illicit
Clodronic AcidDoxorubicin may increase the hypocalcemic activities of Clodronate.Approved, Investigational, Vet Approved
ClofazimineThe serum concentration of Doxorubicin can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Doxorubicin.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Doxorubicin.Approved, Investigational
ClomipramineThe serum concentration of Doxorubicin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Doxorubicin.Approved
ClonixinClonixin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Doxorubicin.Approved, Nutraceutical
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Doxorubicin.Approved, Illicit
ClotrimazoleThe serum concentration of Doxorubicin can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClotrimazoleThe metabolism of Doxorubicin can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxacillinThe serum concentration of Doxorubicin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Clozapine.Approved
ClozapineThe serum concentration of Doxorubicin can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Doxorubicin can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Doxorubicin.Approved
CocaineThe serum concentration of Doxorubicin can be increased when it is combined with Cocaine.Approved, Illicit
CocaineThe metabolism of Doxorubicin can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Doxorubicin can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Doxorubicin can be increased when it is combined with Colforsin.Experimental
ColistimethateDoxorubicin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
ConivaptanThe serum concentration of Doxorubicin can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Doxorubicin.Approved
CrizotinibThe serum concentration of Doxorubicin can be increased when it is combined with Crizotinib.Approved
CrizotinibThe metabolism of Doxorubicin can be decreased when combined with Crizotinib.Approved
CurcuminCurcumin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Doxorubicin can be decreased when it is combined with Cyclacillin.Approved
CyclophosphamideThe serum concentration of Doxorubicin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Doxorubicin.Approved, Investigational
CyclosporineThe serum concentration of Doxorubicin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineDoxorubicin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Doxorubicin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Doxorubicin.Approved
DabrafenibThe serum concentration of Doxorubicin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Doxorubicin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Doxorubicin can be increased when it is combined with Dactinomycin.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Doxorubicin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Doxorubicin.Approved
DarifenacinThe serum concentration of Doxorubicin can be increased when it is combined with Darifenacin.Approved, Investigational
DarifenacinThe metabolism of Doxorubicin can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Doxorubicin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Doxorubicin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Daunorubicin.Approved
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Doxorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Doxorubicin.Approved
DecamethoniumDoxorubicin may increase the respiratory depressant activities of Decamethonium.Approved
DeferasiroxThe serum concentration of Doxorubicin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Doxorubicin can be increased when it is combined with Delavirdine.Approved
DelavirdineThe metabolism of Doxorubicin can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Doxorubicin.Approved
DesipramineThe serum concentration of Doxorubicin can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Doxorubicin.Approved
DesloratadineThe serum concentration of Doxorubicin can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Doxorubicin can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexamethasoneThe serum concentration of Doxorubicin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneThe therapeutic efficacy of Doxorubicin can be decreased when used in combination with Dexrazoxane.Approved, Withdrawn
DextromethorphanThe serum concentration of Doxorubicin can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Doxorubicin.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Doxorubicin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenacDiclofenac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Doxorubicin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Doxorubicin.Approved
DiflunisalDiflunisal may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Doxorubicin.Approved
DigoxinThe serum concentration of Doxorubicin can be increased when it is combined with Digoxin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Doxorubicin.Approved
DihydroergotamineThe serum concentration of Doxorubicin can be increased when it is combined with Dihydroergotamine.Approved
DihydroergotamineThe metabolism of Doxorubicin can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Doxorubicin.Illicit
DiltiazemThe serum concentration of Doxorubicin can be increased when it is combined with Diltiazem.Approved
DiltiazemThe metabolism of Doxorubicin can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe serum concentration of Doxorubicin can be increased when it is combined with Diphenhydramine.Approved
DiphenhydramineThe metabolism of Doxorubicin can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Doxorubicin can be increased when it is combined with Dipyridamole.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Doxorubicin.Approved
DocetaxelThe metabolism of Doxorubicin can be decreased when combined with Docetaxel.Approved, Investigational
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Doxorubicin.Approved, Investigational
Domoic AcidDoxorubicin may increase the respiratory depressant activities of Domoic Acid.Experimental
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Doxorubicin.Approved, Investigational, Vet Approved
Doxacurium chlorideDoxorubicin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DoxazosinThe serum concentration of Doxorubicin can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxorubicin can be increased when it is combined with Doxepin.Approved
DoxycyclineThe serum concentration of Doxorubicin can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxycyclineThe metabolism of Doxorubicin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Doxorubicin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Doxorubicin can be increased when it is combined with Dronedarone.Approved
DronedaroneThe metabolism of Doxorubicin can be decreased when combined with Dronedarone.Approved
DroxicamDroxicam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
DuloxetineThe serum concentration of Doxorubicin can be increased when it is combined with Duloxetine.Approved
DuloxetineThe metabolism of Doxorubicin can be decreased when combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
E-6201E6201 may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
EbselenEbselen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Doxorubicin.Approved
EfavirenzThe serum concentration of Doxorubicin can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Doxorubicin can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Doxorubicin.Approved, Investigational
EliglustatThe serum concentration of Doxorubicin can be increased when it is combined with Eliglustat.Approved
EliglustatThe metabolism of Doxorubicin can be decreased when combined with Eliglustat.Approved
EltrombopagThe serum concentration of Doxorubicin can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Doxorubicin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Doxorubicin can be increased when it is combined with Enzalutamide.Approved
EnzalutamideThe serum concentration of Doxorubicin can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Doxorubicin.Approved, Investigational
EpirizoleEpirizole may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
ErgonovineThe serum concentration of Doxorubicin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Doxorubicin can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Doxorubicin.Approved, Investigational
ErythromycinThe serum concentration of Doxorubicin can be increased when it is combined with Erythromycin.Approved, Vet Approved
ErythromycinThe metabolism of Doxorubicin can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Doxorubicin can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Doxorubicin.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Doxorubicin can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Doxorubicin can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Doxorubicin can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Doxorubicin.Approved
EtanerceptEtanercept may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Doxorubicin.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Doxorubicin.Approved, Illicit
Etidronic acidDoxorubicin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
EtoposideThe serum concentration of Doxorubicin can be increased when it is combined with Etoposide.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Doxorubicin.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
EtravirineThe serum concentration of Doxorubicin can be increased when it is combined with Etravirine.Approved
EtravirineThe serum concentration of Doxorubicin can be decreased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Doxorubicin.Approved
exisulindexisulind may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Doxorubicin.Approved
FelodipineThe serum concentration of Doxorubicin can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
FentanylThe serum concentration of Doxorubicin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Doxorubicin.Approved
FexofenadineThe serum concentration of Doxorubicin can be increased when it is combined with Fexofenadine.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Doxorubicin.Approved
FidaxomicinThe serum concentration of Doxorubicin can be increased when it is combined with Fidaxomicin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Doxorubicin.Approved
FingolimodDoxorubicin may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FloctafenineFloctafenine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Doxorubicin can be decreased when it is combined with Flucloxacillin.Approved
FluconazoleThe metabolism of Doxorubicin can be decreased when combined with Fluconazole.Approved
FluconazoleThe serum concentration of Doxorubicin can be increased when it is combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Doxorubicin.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Doxorubicin.Approved, Illicit
FlunixinFlunixin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Vet Approved
FluoxetineThe serum concentration of Doxorubicin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxetineThe metabolism of Doxorubicin can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Doxorubicin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Doxorubicin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Doxorubicin can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Doxorubicin.Approved
FluvoxamineThe serum concentration of Doxorubicin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FluvoxamineThe metabolism of Doxorubicin can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Doxorubicin can be increased when it is combined with Fosamprenavir.Approved
FosamprenavirThe metabolism of Doxorubicin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Doxorubicin can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the nephrotoxic activities of Doxorubicin.Approved
FosphenytoinThe serum concentration of Doxorubicin can be decreased when it is combined with Fosphenytoin.Approved
FosphenytoinThe metabolism of Doxorubicin can be increased when combined with Fosphenytoin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Doxorubicin.Approved, Vet Approved
Fusidic AcidThe serum concentration of Doxorubicin can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Doxorubicin is combined with G17DT.Investigational
Gallamine TriethiodideDoxorubicin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GefitinibThe serum concentration of Doxorubicin can be increased when it is combined with Gefitinib.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Doxorubicin.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Doxorubicin.Approved
GenisteinThe serum concentration of Doxorubicin can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Doxorubicin is combined with GI-5005.Investigational
GlyburideThe serum concentration of Doxorubicin can be increased when it is combined with Glyburide.Approved
Gramicidin DThe serum concentration of Doxorubicin can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Doxorubicin.Approved
GrepafloxacinThe serum concentration of Doxorubicin can be increased when it is combined with Grepafloxacin.Withdrawn
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Doxorubicin.Withdrawn
HaloperidolThe serum concentration of Doxorubicin can be increased when it is combined with Haloperidol.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Doxorubicin.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Doxorubicin.Approved, Vet Approved
HigenamineHigenamine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
HydrocortisoneThe serum concentration of Doxorubicin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Doxorubicin.Approved, Vet Approved
IbandronateDoxorubicin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
IdelalisibThe serum concentration of Doxorubicin can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Doxorubicin.Approved
ImatinibThe serum concentration of Doxorubicin can be increased when it is combined with Imatinib.Approved
ImatinibThe metabolism of Doxorubicin can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Doxorubicin can be increased when it is combined with Imipramine.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Doxorubicin.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Doxorubicin.Approved
IndinavirThe serum concentration of Doxorubicin can be increased when it is combined with Indinavir.Approved
IndinavirThe metabolism of Doxorubicin can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Doxorubicin can be increased when it is combined with Indomethacin.Approved, Investigational
IndomethacinIndomethacin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Doxorubicin is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Doxorubicin is combined with INGN 225.Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Doxorubicin.Approved, Investigational
IsavuconazoniumThe serum concentration of Doxorubicin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsavuconazoniumThe metabolism of Doxorubicin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Doxorubicin.Approved, Vet Approved
IsoniazidThe serum concentration of Doxorubicin can be increased when it is combined with Isoniazid.Approved
IsoniazidThe metabolism of Doxorubicin can be decreased when combined with Isoniazid.Approved
IsoxicamIsoxicam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Withdrawn
IsradipineThe serum concentration of Doxorubicin can be increased when it is combined with Isradipine.Approved
IsradipineThe metabolism of Doxorubicin can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Doxorubicin can be increased when it is combined with Itraconazole.Approved, Investigational
ItraconazoleThe metabolism of Doxorubicin can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Doxorubicin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Doxorubicin can be increased when it is combined with Ivermectin.Approved, Vet Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Doxorubicin.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Doxorubicin.Approved
KebuzoneKebuzone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Experimental
KetamineThe serum concentration of Doxorubicin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Doxorubicin.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Doxorubicin.Approved
KetoconazoleThe serum concentration of Doxorubicin can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Doxorubicin can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Doxorubicin.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Doxorubicin.Approved, Investigational
LansoprazoleThe serum concentration of Doxorubicin can be increased when it is combined with Lansoprazole.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Doxorubicin.Approved, Investigational
LapatinibThe serum concentration of Doxorubicin can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Doxorubicin.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Doxorubicin.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Doxorubicin.Approved
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Doxorubicin.Approved, Investigational
LevofloxacinThe serum concentration of Doxorubicin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Doxorubicin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Doxorubicin.Approved
LevothyroxineThe serum concentration of Doxorubicin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Doxorubicin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Doxorubicin.Approved
LiothyronineThe serum concentration of Doxorubicin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Doxorubicin can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Doxorubicin can be increased when it is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
LomitapideThe serum concentration of Doxorubicin can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Doxorubicin can be increased when it is combined with Loperamide.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Doxorubicin.Approved
LopinavirThe serum concentration of Doxorubicin can be increased when it is combined with Lopinavir.Approved
LopinavirThe metabolism of Doxorubicin can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Doxorubicin can be increased when it is combined with Loratadine.Approved
LorcaserinThe serum concentration of Doxorubicin can be increased when it is combined with Lorcaserin.Approved
LorcaserinThe metabolism of Doxorubicin can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
LosartanThe serum concentration of Doxorubicin can be increased when it is combined with Losartan.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Doxorubicin.Approved
LovastatinThe serum concentration of Doxorubicin can be increased when it is combined with Lovastatin.Approved, Investigational
LovastatinThe metabolism of Doxorubicin can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
LuliconazoleThe serum concentration of Doxorubicin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Doxorubicin can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Doxorubicin can be increased when it is combined with Lumefantrine.Approved
LumefantrineThe metabolism of Doxorubicin can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
MalathionThe metabolism of Malathion can be decreased when combined with Doxorubicin.Approved, Investigational
MannitolMannitol may increase the nephrotoxic activities of Doxorubicin.Approved, Investigational
MaprotilineThe serum concentration of Doxorubicin can be increased when it is combined with Maprotiline.Approved
MasoprocolMasoprocol may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
MebendazoleThe serum concentration of Doxorubicin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineDoxorubicin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
MefloquineThe serum concentration of Doxorubicin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Doxorubicin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Doxorubicin.Investigational, Withdrawn
MeprobamateThe serum concentration of Doxorubicin can be increased when it is combined with Meprobamate.Approved, Illicit
MercaptopurineDoxorubicin may increase the hepatotoxic activities of Mercaptopurine.Approved
MesalazineMesalazine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Doxorubicin.Withdrawn
MethadoneThe serum concentration of Doxorubicin can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Doxorubicin.Approved
MethotrimeprazineThe serum concentration of Doxorubicin can be increased when it is combined with Methotrimeprazine.Approved
MethotrimeprazineThe metabolism of Doxorubicin can be decreased when combined with Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Doxorubicin.Approved, Vet Approved
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Doxorubicin.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Doxorubicin.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Doxorubicin.Approved
MeticillinThe serum concentration of Doxorubicin can be decreased when it is combined with Meticillin.Approved
MetocurineDoxorubicin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideDoxorubicin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Doxorubicin.Approved, Investigational
MexiletineThe metabolism of Mexiletine can be decreased when combined with Doxorubicin.Approved
MezlocillinThe serum concentration of Doxorubicin can be decreased when it is combined with Mezlocillin.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Doxorubicin.Approved
MibefradilThe serum concentration of Doxorubicin can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Doxorubicin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Doxorubicin can be increased when it is combined with Midazolam.Approved, Illicit
MidazolamThe serum concentration of Doxorubicin can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Doxorubicin can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Doxorubicin.Approved
MirabegronThe serum concentration of Doxorubicin can be increased when it is combined with Mirabegron.Approved
MitomycinThe serum concentration of Doxorubicin can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Doxorubicin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Doxorubicin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MitoxantroneThe serum concentration of Doxorubicin can be increased when it is combined with Mitoxantrone.Approved, Investigational
MivacuriumDoxorubicin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
ModafinilThe serum concentration of Doxorubicin can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Doxorubicin can be increased when it is combined with Morphine.Approved, Investigational
MorphineThe serum concentration of Morphine can be decreased when it is combined with Doxorubicin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
NadololThe serum concentration of Nadolol can be decreased when it is combined with Doxorubicin.Approved
NafamostatNafamostat may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Doxorubicin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Doxorubicin.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Doxorubicin.Approved, Vet Approved
NaltrexoneThe serum concentration of Doxorubicin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenNaproxen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Vet Approved
NaringeninThe serum concentration of Doxorubicin can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Doxorubicin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NefazodoneThe metabolism of Doxorubicin can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Doxorubicin can be increased when it is combined with Nelfinavir.Approved
NelfinavirThe metabolism of Doxorubicin can be decreased when combined with Nelfinavir.Approved
NeosaxitoxinDoxorubicin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NeostigmineThe serum concentration of Doxorubicin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NepafenacNepafenac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
NetupitantThe serum concentration of Doxorubicin can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Doxorubicin can be increased when it is combined with Nevirapine.Approved
NevirapineThe metabolism of Doxorubicin can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Doxorubicin can be increased when it is combined with Nicardipine.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Doxorubicin.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Doxorubicin.Approved
NifedipineThe serum concentration of Doxorubicin can be increased when it is combined with Nifedipine.Approved
NifedipineThe serum concentration of Doxorubicin can be decreased when it is combined with Nifedipine.Approved
Niflumic AcidNiflumic Acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
NilotinibThe serum concentration of Doxorubicin can be increased when it is combined with Nilotinib.Approved, Investigational
NilotinibThe metabolism of Doxorubicin can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideNimesulide may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Withdrawn
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Doxorubicin.Approved
NisoldipineThe serum concentration of Doxorubicin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Doxorubicin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Doxorubicin can be increased when it is combined with Nitrendipine.Approved
NitroaspirinNitroaspirin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Doxorubicin.Approved
NorethisteroneThe serum concentration of Doxorubicin can be decreased when it is combined with Norethisterone.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Doxorubicin.Approved, Investigational
OlaparibThe serum concentration of Doxorubicin can be increased when it is combined with Olaparib.Approved
OlaparibThe metabolism of Doxorubicin can be decreased when combined with Olaparib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Doxorubicin.Experimental
OlopatadineOlopatadine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Doxorubicin.Approved
OmeprazoleThe serum concentration of Doxorubicin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinOrgotein may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Vet Approved
OsimertinibThe serum concentration of Doxorubicin can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Doxorubicin.Approved
OuabainOuabain may decrease the cardiotoxic activities of Doxorubicin.Approved
OxacillinThe serum concentration of Doxorubicin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Withdrawn
P-NitrophenolThe serum concentration of Doxorubicin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Doxorubicin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Doxorubicin.Approved, Vet Approved
PalbociclibThe serum concentration of Doxorubicin can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Doxorubicin can be increased when it is combined with Palmitic Acid.Experimental
PamidronateDoxorubicin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumDoxorubicin may increase the respiratory depressant activities of Pancuronium.Approved
PanobinostatThe serum concentration of Doxorubicin can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Doxorubicin can be increased when it is combined with Pantoprazole.Approved
ParecoxibParecoxib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
ParoxetineThe serum concentration of Doxorubicin can be increased when it is combined with Paroxetine.Approved, Investigational
ParoxetineThe metabolism of Doxorubicin can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Doxorubicin.Approved
Peginterferon alfa-2bThe serum concentration of Doxorubicin can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe serum concentration of Doxorubicin can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PentobarbitalThe metabolism of Doxorubicin can be increased when combined with Pentobarbital.Approved, Vet Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Doxorubicin.Approved
PerindoprilThe serum concentration of Doxorubicin can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Doxorubicin.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Doxorubicin.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Doxorubicin.Approved
PhenobarbitalThe serum concentration of Doxorubicin can be decreased when it is combined with Phenobarbital.Approved
PhenobarbitalThe metabolism of Doxorubicin can be increased when combined with Phenobarbital.Approved
PhenoxymethylpenicillinThe serum concentration of Doxorubicin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Vet Approved
PhenytoinThe serum concentration of Doxorubicin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhenytoinThe metabolism of Doxorubicin can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Doxorubicin.Approved, Investigational
PimozideThe serum concentration of Doxorubicin can be increased when it is combined with Pimozide.Approved
PipecuroniumDoxorubicin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Doxorubicin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Doxorubicin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Doxorubicin.Approved
PivampicillinThe serum concentration of Doxorubicin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Doxorubicin can be decreased when it is combined with Pivmecillinam.Approved
Platelet Activating FactorThe serum concentration of Doxorubicin can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Doxorubicin.Approved
PonatinibThe serum concentration of Doxorubicin can be increased when it is combined with Ponatinib.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Doxorubicin.Approved
PosaconazoleThe serum concentration of Doxorubicin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PosaconazoleThe metabolism of Doxorubicin can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Doxorubicin.Approved
PravastatinThe serum concentration of Doxorubicin can be increased when it is combined with Pravastatin.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Doxorubicin.Approved
PrazosinThe serum concentration of Doxorubicin can be increased when it is combined with Prazosin.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Doxorubicin.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Doxorubicin.Approved, Vet Approved
PrednisoneThe serum concentration of Doxorubicin can be increased when it is combined with Prednisone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Doxorubicin.Approved, Vet Approved
PrimidoneThe serum concentration of Doxorubicin can be decreased when it is combined with Primidone.Approved, Vet Approved
PrimidoneThe metabolism of Doxorubicin can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Doxorubicin can be increased when it is combined with Probenecid.Approved
Procaine benzylpenicillinThe serum concentration of Doxorubicin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProgesteroneThe serum concentration of Doxorubicin can be increased when it is combined with Progesterone.Approved, Vet Approved
ProgesteroneThe serum concentration of Doxorubicin can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe serum concentration of Doxorubicin can be increased when it is combined with Promazine.Approved, Vet Approved
PromazineThe metabolism of Doxorubicin can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Doxorubicin can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
PropafenoneThe serum concentration of Doxorubicin can be increased when it is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Doxorubicin.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Doxorubicin can be increased when it is combined with Propranolol.Approved, Investigational
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Doxorubicin.Approved, Investigational
ProtriptylineThe serum concentration of Doxorubicin can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Doxorubicin.Approved
PTC299PTC299 may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
PyrantelDoxorubicin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
QuercetinThe serum concentration of Doxorubicin can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Doxorubicin.Approved
QuinacrineThe serum concentration of Doxorubicin can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Doxorubicin can be increased when it is combined with Quinidine.Approved
QuinidineThe metabolism of Doxorubicin can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Doxorubicin can be increased when it is combined with Quinine.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Doxorubicin.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Rabies vaccine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Doxorubicin.Approved
RanitidineThe serum concentration of Doxorubicin can be increased when it is combined with Ranitidine.Approved
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Doxorubicin.Approved
RanolazineThe serum concentration of Doxorubicin can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumDoxorubicin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ReboxetineThe serum concentration of Doxorubicin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Doxorubicin can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Doxorubicin can be increased when it is combined with Reserpine.Approved
ReserpineThe serum concentration of Doxorubicin can be decreased when it is combined with Reserpine.Approved
ResveratrolResveratrol may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Experimental, Investigational
RifabutinThe serum concentration of Doxorubicin can be decreased when it is combined with Rifabutin.Approved
RifabutinThe metabolism of Doxorubicin can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Doxorubicin can be increased when it is combined with Rifampicin.Approved
RifampicinThe metabolism of Doxorubicin can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of Doxorubicin can be decreased when it is combined with Rifapentine.Approved
RifapentineThe metabolism of Doxorubicin can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Doxorubicin.Approved, Investigational
RilpivirineThe serum concentration of Doxorubicin can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Doxorubicin is combined with CDX-110.Investigational
RisedronateDoxorubicin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Doxorubicin.Approved, Investigational
RitonavirThe serum concentration of Doxorubicin can be increased when it is combined with Ritonavir.Approved, Investigational
RitonavirThe metabolism of Doxorubicin can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Doxorubicin.Approved
RocuroniumDoxorubicin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Doxorubicin.Approved
RolapitantThe serum concentration of Doxorubicin can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Doxorubicin.Approved, Investigational
RopiniroleThe serum concentration of Doxorubicin can be increased when it is combined with Ropinirole.Approved, Investigational
RopiniroleThe metabolism of Doxorubicin can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Doxorubicin.Approved
SalicylamideSalicylamide may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
SaquinavirThe serum concentration of Doxorubicin can be increased when it is combined with Saquinavir.Approved, Investigational
SaquinavirThe metabolism of Doxorubicin can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Doxorubicin can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Doxorubicin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Doxorubicin.Approved
SeratrodastSeratrodast may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
SertralineThe serum concentration of Doxorubicin can be increased when it is combined with Sertraline.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Doxorubicin.Approved, Vet Approved
SildenafilThe serum concentration of Doxorubicin can be increased when it is combined with Sildenafil.Approved, Investigational
SildenafilThe metabolism of Doxorubicin can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Doxorubicin.Approved
SiltuximabThe serum concentration of Doxorubicin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Doxorubicin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Doxorubicin can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Doxorubicin.Approved
SirolimusThe serum concentration of Doxorubicin can be increased when it is combined with Sirolimus.Approved, Investigational
SirolimusThe serum concentration of Doxorubicin can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Doxorubicin.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Doxorubicin.Approved
SorafenibThe serum concentration of Doxorubicin can be increased when it is combined with Sorafenib.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Doxorubicin.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Doxorubicin.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Doxorubicin.Experimental
SpironolactoneThe serum concentration of Doxorubicin can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Doxorubicin is combined with SRP 299.Investigational
SRT501SRT501 may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
St. John's WortThe serum concentration of Doxorubicin can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StaurosporineThe serum concentration of Doxorubicin can be increased when it is combined with Staurosporine.Experimental
StavudineThe therapeutic efficacy of Stavudine can be decreased when used in combination with Doxorubicin.Approved, Investigational
StiripentolThe serum concentration of Doxorubicin can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Doxorubicin can be decreased when it is combined with Streptozocin.Approved
SuccinylcholineDoxorubicin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Doxorubicin can be decreased when it is combined with Sulbactam.Approved
SulfasalazineSulfasalazine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
SulfinpyrazoneThe serum concentration of Doxorubicin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Doxorubicin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulfisoxazoleThe serum concentration of Doxorubicin can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Doxorubicin can be decreased when it is combined with Sultamicillin.Investigational
SumatriptanThe serum concentration of Doxorubicin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Doxorubicin can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenSuprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Withdrawn
TacrineThe serum concentration of Doxorubicin can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Doxorubicin.Approved, Investigational
TacrolimusThe serum concentration of Doxorubicin can be increased when it is combined with Tacrolimus.Approved, Investigational
TacrolimusThe serum concentration of Doxorubicin can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Doxorubicin can be increased when it is combined with Tamoxifen.Approved
TamoxifenThe serum concentration of Doxorubicin can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Doxorubicin can be increased when it is combined with Taurocholic Acid.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Doxorubicin.Experimental
TazobactamThe serum concentration of Doxorubicin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateDoxorubicin may increase the hypocalcemic activities of Technetium tc 99m etidronate.Approved
Technetium Tc-99m medronateDoxorubicin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Doxorubicin.Approved
TelaprevirThe serum concentration of Doxorubicin can be increased when it is combined with Telaprevir.Withdrawn
TelaprevirThe metabolism of Doxorubicin can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe serum concentration of Doxorubicin can be increased when it is combined with Telithromycin.Approved
TelithromycinThe metabolism of Doxorubicin can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Doxorubicin can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Doxorubicin.Approved
TemsirolimusThe serum concentration of Doxorubicin can be increased when it is combined with Temsirolimus.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Doxorubicin.Approved
Tenofovir disoproxilThe serum concentration of Doxorubicin can be increased when it is combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Vet Approved
TerazosinThe serum concentration of Doxorubicin can be increased when it is combined with Terazosin.Approved
TerbinafineThe serum concentration of Doxorubicin can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbinafineThe metabolism of Doxorubicin can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Doxorubicin can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Doxorubicin can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Doxorubicin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Doxorubicin can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Doxorubicin is combined with TG4010.Investigational
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Doxorubicin.Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
TicagrelorThe serum concentration of Doxorubicin can be increased when it is combined with Ticagrelor.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Doxorubicin.Approved
TicarcillinThe serum concentration of Doxorubicin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
TiclopidineThe serum concentration of Doxorubicin can be increased when it is combined with Ticlopidine.Approved
TiclopidineThe metabolism of Doxorubicin can be decreased when combined with Ticlopidine.Approved
Tiludronic acidDoxorubicin may increase the hypocalcemic activities of Tiludronate.Approved, Vet Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Doxorubicin.Approved
TinoridineTinoridine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational
TipranavirThe serum concentration of Doxorubicin can be increased when it is combined with Tipranavir.Approved, Investigational
TipranavirThe metabolism of Doxorubicin can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Doxorubicin can be decreased when it is combined with Tocilizumab.Approved
TofacitinibDoxorubicin may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
TolvaptanThe serum concentration of Doxorubicin can be increased when it is combined with Tolvaptan.Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Doxorubicin.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Doxorubicin.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Doxorubicin.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Doxorubicin.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Doxorubicin.Approved, Investigational
TranilastTranilast may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
TranylcypromineThe serum concentration of Doxorubicin can be increased when it is combined with Tranylcypromine.Approved
TranylcypromineThe metabolism of Doxorubicin can be decreased when combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Doxorubicin.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Doxorubicin.Approved
TrazodoneThe serum concentration of Doxorubicin can be decreased when it is combined with Trazodone.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Doxorubicin.Approved, Investigational, Nutraceutical
TrifluoperazineThe serum concentration of Doxorubicin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Doxorubicin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Doxorubicin can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimethoprimThe serum concentration of Doxorubicin can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Doxorubicin can be increased when it is combined with Trimipramine.Approved
TubocurarineDoxorubicin may increase the respiratory depressant activities of Tubocurarine.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Doxorubicin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Doxorubicin.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Doxorubicin.Approved, Investigational
VancomycinVancomycin may increase the nephrotoxic activities of Doxorubicin.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Doxorubicin.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Doxorubicin.Approved
VenlafaxineThe serum concentration of Doxorubicin can be increased when it is combined with Venlafaxine.Approved
VenlafaxineThe metabolism of Doxorubicin can be decreased when combined with Venlafaxine.Approved
VerapamilThe serum concentration of Doxorubicin can be increased when it is combined with Verapamil.Approved
VerapamilThe metabolism of Doxorubicin can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Doxorubicin can be increased when it is combined with Vinblastine.Approved
VinblastineThe serum concentration of Doxorubicin can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Doxorubicin.Approved, Investigational
VincristineThe serum concentration of Doxorubicin can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Doxorubicin can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Doxorubicin.Approved
VoriconazoleThe serum concentration of Doxorubicin can be increased when it is combined with Voriconazole.Approved, Investigational
VoriconazoleThe metabolism of Doxorubicin can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Doxorubicin.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved
ZidovudineThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Zidovudine.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Doxorubicin.Approved
ZileutonZileuton may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Doxorubicin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Doxorubicin can be increased when it is combined with Ziprasidone.Approved
ZiprasidoneThe metabolism of Doxorubicin can be decreased when combined with Ziprasidone.Approved
Zoledronic acidDoxorubicin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Withdrawn
Food Interactions
  • Liberal fluid intake to increase urine output and help the excretion of uric acid.
References
Synthesis Reference

Gian P. Vicario, Sergio Penco, Federico Arcamone, "Daunorubicin and doxorubicin labelled with .sup.14 C at the 14-position and processes for their preparation." U.S. Patent US4211864, issued March, 1976.

US4211864
General References
  1. Weiss RB: The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992 Dec;19(6):670-86. [PubMed:1462166 ]
  2. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA: Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967 Mar;20(3):333-53. [PubMed:4290058 ]
  3. Arcamone F, Cassinelli G, Fantini G, Grein A, Orezzi P, Pol C, Spalla C: Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng. 1969 Nov;11(6):1101-10. [PubMed:5365804 ]
  4. Di Marco A, Gaetani M, Scarpinato B: Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep. 1969 Feb;53(1):33-7. [PubMed:5772652 ]
  5. Lomovskaya N, Otten SL, Doi-Katayama Y, Fonstein L, Liu XC, Takatsu T, Inventi-Solari A, Filippini S, Torti F, Colombo AL, Hutchinson CR: Doxorubicin overproduction in Streptomyces peucetius: cloning and characterization of the dnrU ketoreductase and dnrV genes and the doxA cytochrome P-450 hydroxylase gene. J Bacteriol. 1999 Jan;181(1):305-18. [PubMed:9864344 ]
  6. Mordente A, Meucci E, Silvestrini A, Martorana GE, Giardina B: New developments in anthracycline-induced cardiotoxicity. Curr Med Chem. 2009;16(13):1656-72. [PubMed:19442138 ]
  7. Minotti G: Reactions of adriamycin with microsomal iron and lipids. Free Radic Res Commun. 1989;7(3-6):143-8. [PubMed:2555273 ]
External Links
ATC CodesL01DB01 — Doxorubicin
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (105 KB)
MSDSDownload (74.1 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingBasic ScienceSoft Tissue Sarcoma (STS)1
1Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
1Active Not RecruitingTreatmentBurkitt's Lymphoma / Follicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1Active Not RecruitingTreatmentCancer, Breast / Gastrointestinal Cancers / Genitourinary Cancers / Gynecologic Cancers / Sarcomas1
1Active Not RecruitingTreatmentCancer, Ovarian1
1Active Not RecruitingTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Male Breast Carcinoma / Progesterone Receptor Negative / Recurrent Breast Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
1Active Not RecruitingTreatmentLiver Cancer1
1Active Not RecruitingTreatmentLymphoma, Hodgkins1
1Active Not RecruitingTreatmentMalignant Lymphomas / Mantle Cell Lymphoma (MCL)1
1Active Not RecruitingTreatmentNeoplasms1
1Active Not RecruitingTreatmentSarcomas1
1Active Not RecruitingTreatmentSolid Neoplasms / Stage III Non-Hodgkin Lymphoma / Stage IV Non-Hodgkin Lymphoma1
1Active Not RecruitingTreatmentTumors, Solid / Urethral Cancer1
1CompletedTreatmentAdrenocortical Carcinoma / Cancer, Breast / Colorectal Cancers / Prostate Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentAdult Angiosarcoma / Adult Desmoplastic Small Round Cell Tumor / Adult Epithelioid Sarcoma / Adult Extraskeletal Myxoid Chondrosarcoma / Adult Extraskeletal Osteosarcoma / Adult Fibrosarcoma / Adult Leiomyosarcoma / Adult Liposarcoma / Adult Malignant Mesenchymoma / Adult Malignant Peripheral Nerve Sheath Tumor / Adult Rhabdomyosarcoma / Adult Synovial Sarcoma / Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone / Childhood Angiosarcoma / Childhood Desmoplastic Small Round Cell Tumor / Childhood Epithelioid Sarcoma / Childhood Fibrosarcoma / Childhood Leiomyosarcoma / Childhood Liposarcoma / Childhood Malignant Mesenchymoma / Childhood Malignant Peripheral Nerve Sheath Tumor / Childhood Pleomorphic Rhabdomyosarcoma / Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features / Childhood Synovial Sarcoma / Dermatofibrosarcoma Protuberans / Malignant Adult Hemangiopericytoma / Malignant Childhood Hemangiopericytoma / Metastatic Childhood Soft Tissue Sarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Rhabdomyosarcoma / Recurrent Childhood Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
1CompletedTreatmentAdvanced Solid Tumours1
1CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter2
1CompletedTreatmentCancer, Advanced4
1CompletedTreatmentCancer, Breast5
1CompletedTreatmentCancer, Breast / Chronic Myeloproliferative Disorders / Colorectal Cancers / Head and Neck Carcinoma / Leukemias / Lung Cancers / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic/Myeloproliferative Diseases / Prostate Cancer / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancer, Ovarian1
1CompletedTreatmentCancers1
1CompletedTreatmentCancers / Sarcomas1
1CompletedTreatmentCardiac Toxicity / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Clear Cell Adenocarcinoma / Endometrial Serous Adenocarcinoma / Stage III Uterine Corpus Cancer / Stage IV Uterine Corpus Cancer1
1CompletedTreatmentEndometrial Adenocarcinomas / Neuroendocrine Tumors / Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy / Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy)1
1CompletedTreatmentEndometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Mixed Adenocarcinoma / Endometrial Serous Adenocarcinoma / Endometrial Squamous Cell Carcinoma / Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
1CompletedTreatmentEwing's Sarcoma (ES) / Neuroectodermal Tumors, Primitive / Neuroepithelioma / Sarcoma, Osteogenic / Sarcomas1
1CompletedTreatmentGastrointestinal Stromal Tumors / Recurrent Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
1CompletedTreatmentHepatocellular,Carcinoma / Liver Cancer / Localized Unresectable Liver Cancer1
1CompletedTreatmentHepatocellular,Carcinoma / Neoplasms1
1CompletedTreatmentHepatocellular,Carcinoma / Neoplasms, Hepatic1
1CompletedTreatmentHodgkins Disease (HD)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)3
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukemias / Malignant Lymphomas1
1CompletedTreatmentLung Cancers / Mesothelioma, Malignant / Metastatic Cancers1
1CompletedTreatmentLung Cancers / Metastatic Cancers1
1CompletedTreatmentLymphoma, Large-Cell, Anaplastic / Lymphoma, NK-cell / T-Cell Lymphomas1
1CompletedTreatmentMalignant Gliomas1
1CompletedTreatmentMalignant Lymphomas2
1CompletedTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Cystadenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Ovarian Carcinoma1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentNeoplasms, Breast1
1CompletedTreatmentNeoplasms, Hepatic1
1CompletedTreatmentNeoplasms / Neoplasms by Histologic Type / Neoplasms, Connective and Soft Tissue / Sarcomas / Soft Tissue Sarcoma (STS)1
1CompletedTreatmentNeuroblastomas2
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
1CompletedTreatmentOvarian Epithelial Cancer Recurrent1
1CompletedTreatmentPeripheral T-Cell Lymphoma (PTCL)1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentRecurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer1
1CompletedTreatmentRecurrent Neuroblastoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentResistant Solid Malignancies1
1CompletedTreatmentSarcomas4
1CompletedTreatmentSarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentSoft Tissue Sarcoma (STS)1
1CompletedTreatmentTumors, Solid2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific4
1Not Yet RecruitingTreatmentCD20 Positive / HIV Positivity / Lymphoma, AIDS Related / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
1Not Yet RecruitingTreatmentMalignant Neoplasms of Mesothelial and Soft Tissue / Rhabdomyosarcoma, Abdominal / Rhabdomyosarcoma, Pelvic1
1Not Yet RecruitingTreatmentSarcomas1
1Not Yet RecruitingTreatmentSoft Tissue Sarcoma (STS)1
1RecruitingBasic ScienceSoft Tissue Sarcoma Adult1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B-cell Adult Acute Lymphoblastic Leukemia / Lymphoma, Lymphoblastic / T-cell Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentAdvanced Cancers1
1RecruitingTreatmentAdvanced Solid Tumors Amenable to Anthracycline Therapy / Sarcoma, Breast Cancer, Lung Carcinomas, and Gynecological Cancer Amenable to Anthracycline Therapy1
1RecruitingTreatmentAnaplastic Astrocytoma (AA) / Astrocytomas / Glioblastomas / Gliomas / Mixed Gliomas / Oligoastrocytoma, Mixed / Oligodendrogliomas / Optic Nerve Glioma / Pilocytic Astrocytoma1
1RecruitingTreatmentCancer, Ovarian1
1RecruitingTreatmentContiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentCutaneous Lymphomas / Malignant Lymphomas / T-Cell Lymphomas1
1RecruitingTreatmentCutaneous T Cell Lymphomas (CTCL)1
1RecruitingTreatmentDiffuse Large B-Cell Lymphoma, Lymphoma Follicular / Diffuse Large B-Cell Lymphoma, Lymphoma, Follicular1
1RecruitingTreatmentEndometrial Cancers / Fallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
1RecruitingTreatmentEwing's Sarcoma (ES) / Germ Cell Tumors / Hepatic Tumors / Neuroblastomas / Pediatric Cancer / Rhabdomyosarcomas / Sarcoma, Osteogenic / Soft Tissue Sarcoma (STS) / Tumors, Solid / Wilms' tumor1
1RecruitingTreatmentEwing's Sarcoma (ES) / Neuroblastomas / Rhabdomyosarcomas / Sarcoma, Osteogenic / Sarcomas1
1RecruitingTreatmentFallopian Tube Cancer / Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
1RecruitingTreatmentGlioblastomas1
1RecruitingTreatmentHER2 Positive Breast Cancers / HER2-negative Metastatic Breast Cancer / HER2-positive Metastatic Breast Cancer / Locally Advanced or Early Breast Cancer1
1RecruitingTreatmentHigh Grade B-cell Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentHodgkins Disease (HD)1
1RecruitingTreatmentLung Cancer Metastatic / Sarcoma, Bone / Soft Tissue Sarcoma (STS)1
1RecruitingTreatmentLymphoma, Hodgkins1
1RecruitingTreatmentMetastatic Angiosarcoma / Metastatic Epithelioid Sarcoma / Metastatic Fibrosarcoma / Metastatic Leiomyosarcoma / Metastatic Liposarcoma / Metastatic Malignant Peripheral Nerve Sheath Tumor / Metastatic Synovial Sarcoma / Metastatic Undifferentiated Pleomorphic Sarcoma / Myxofibrosarcoma / Pleomorphic Rhabdomyosarcoma / Stage III Soft Tissue Sarcoma / Stage IV Soft Tissue Sarcoma / Undifferentiated (Embryonal) Sarcoma1
1RecruitingTreatmentNeoplasms Metastasis1
1RecruitingTreatmentRecurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Neuroblastoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1RecruitingTreatmentRecurrent Small Cell Lung Carcinoma1
1RecruitingTreatmentSoft Tissue Sarcoma (STS)2
1RecruitingTreatmentTriple Negative Breast Neoplasms1
1TerminatedTreatmentAcute Leukemias of Ambiguous Lineage / Acute Undifferentiated Leukemia (AUL) / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Small Intestine Lymphoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1TerminatedTreatmentAcute Lymphoblastic Leukaemia Recurrent / Allergy to Native e.Coli Asparaginase / Allergy to PEG e.Coli Asparaginase1
1TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Recurrent Pediatric ALL / Refractory Pediatric ALL / Relapsed Pediatric ALL1
1TerminatedTreatmentBone Cancer / Kidney Tumors / Neoplasms / Neuroblastomas / Tumors, Solid1
1TerminatedTreatmentCancer, Breast1
1TerminatedTreatmentCancer, Ovarian2
1TerminatedTreatmentCancer, Ovarian / Fallopian Tube Carcinoma / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma1
1TerminatedTreatmentFallopian Tube Neoplasms / Neoplasms / Neoplasms, Ovarian / Primary Peritoneal Neoplasms1
1TerminatedTreatmentHER-2 Positive Breast Cancer / Malignant Neoplasm of Breast1
1TerminatedTreatmentLeukemia, Lymphoblastic, Acute / Leukemia, Lymphoblastic, Acute, T Cell / Lymphoblastic Leukemia, Acute / Lymphoblastic Leukemia, Acute, Childhood1
1TerminatedTreatmentLung Cancer Metastatic / Sarcoma, Osteogenic1
1TerminatedTreatmentMixed Phenotype Acute Leukemia (MPAL) / Relapsed or Refractory Acute Lymphoblastic Leukemia / Relapsed or Refractory Lymphoblastic Lymphoma1
1TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1TerminatedTreatmentStages II-III Breast Cancer1
1Unknown StatusTreatmentCancer, Ovarian / Cancers / Malignant Female Reproductive System Neoplasm / Ovarian Epithelial Cancer Recurrent / Ovarian Tumors1
1Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
1WithdrawnTreatmentCancer, Breast2
1WithdrawnTreatmentLiver Cancer1
1WithdrawnTreatmentMalignant Lymphomas / Tumors, Solid1
1, 2Active Not RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / CD20 Positive / Grade 3b Follicular Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Plasmablastic Lymphoma / Primary Effusion Lymphomas / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
1, 2Active Not RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Progressive Hairy Cell Leukemia, Initial Treatment / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Untreated Hairy Cell Leukemia / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentCancer, Advanced / Cancer, Breast / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Pancreas / Ovarian / Sarcomas1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentDiffuse Large B Cell Lymphoma Refractory / Diffuse Large B Cell Lymphoma Relapsed1
1, 2Active Not RecruitingTreatmentLymphoma, B-Cell, Non-Hodgkin's Lymphoma / Non Hodgkin Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)4
1, 2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia1
1, 2Active Not RecruitingTreatmentStage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
1, 2CompletedPreventionCancer, Advanced / Tumors, Solid1
1, 2CompletedSupportive CareCancer, Breast / Drug/Agent Toxicity by Tissue/Organ1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1, 2CompletedTreatmentAdult T-cell lymphomas/leukaemias1
1, 2CompletedTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T Cell Lymphoma / Cutaneous T Cell Lymphomas (CTCL) / Peripheral T Cell Lymphoma Unspecified1
1, 2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter1
1, 2CompletedTreatmentCancer, Breast3
1, 2CompletedTreatmentCancer, Breast / Cancer, Ovarian / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentCancer, Breast / Male Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
1, 2CompletedTreatmentCancer, Ovarian1
1, 2CompletedTreatmentDose Escalation: Solid Tumors / MTD: Soft Tissue Sarcomas1
1, 2CompletedTreatmentFallopian Tube Cancer / Female Reproductive Cancer / Recurrent Breast Cancer / Recurrent Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Breast Cancer / Stage IV Ovarian Epithelial Cancer1
1, 2CompletedTreatmentFollicular Lymphoma (FL) / Lymphoma, B-Cell1
1, 2CompletedTreatmentGlioblastomas1
1, 2CompletedTreatmentHER2-positive Breast Cancer / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1, 2CompletedTreatmentHead and Neck Carcinoma1
1, 2CompletedTreatmentHodgkins Disease (HD)1
1, 2CompletedTreatmentLocally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma / Sarcomas / Soft Tissue Sarcoma (STS)1
1, 2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large-Cell, Diffuse1
1, 2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2CompletedTreatmentMalignant Lymphomas3
1, 2CompletedTreatmentMalignant Lymphomas / Non Hodgkin Lymphoma (NHL)1
1, 2CompletedTreatmentMetastatic Breast Cancer (MBC)1
1, 2CompletedTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentMultiple Myeloma (MM) / Patient Participation1
1, 2CompletedTreatmentMultiple Myeloma in Relapse1
1, 2CompletedTreatmentProstate Cancer1
1, 2CompletedTreatmentSarcomas4
1, 2Not Yet RecruitingTreatmentAdult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma1
1, 2Not Yet RecruitingTreatmentMalignant Neoplasm of Breast1
1, 2RecruitingTreatmentAIDS-Related Hodgkin Lymphoma / CD30-Positive Neoplastic Cells Present / Classical Hodgkin Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Stage II Hodgkin Lymphoma / Stage IIA Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage III Hodgkin Lymphoma / Stage IIIA Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
1, 2RecruitingTreatmentALK- Anaplastic Large Cell Lymphoma (ALCL) / ALK- Anaplastic Largecell Lymphoma (ALCL) / Angioimmunoblastic T-cell Lymphoma (AITL) / Peripheral T-Cell Lymphoma (PTCL) / Peripheral T-cell Lymphomas Not Otherwise Specified (PTCL-NOS) / PTCL-NOS1
1, 2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage II Angioimmunoblastic T-cell Lymphoma / Stage II Enteropathy-Associated T-Cell Lymphoma / Stage III Angioimmunoblastic T-cell Lymphoma / Stage III Enteropathy-Associated T-Cell Lymphoma / Stage IV Angioimmunoblastic T-cell Lymphoma / Stage IV Enteropathy-Associated T-Cell Lymphoma1
1, 2RecruitingTreatmentBladder Cancers1
1, 2RecruitingTreatmentBreast Adenocarcinoma / Estrogen Receptor Positive / HER2/Neu Negative / Recurrent Breast Carcinoma / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2RecruitingTreatmentCancer, Breast1
1, 2RecruitingTreatmentCancer, Ovarian1
1, 2RecruitingTreatmentCancers1
1, 2RecruitingTreatmentChondrosarcomas / Retroperitoneal Leiomyosarcoma / Retroperitoneal Liposarcoma1
1, 2RecruitingTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
1, 2RecruitingTreatmentLymphoma, B-Cell / Primary Effusion Lymphomas1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)3
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2RecruitingTreatmentMultiple Myeloma (MM)1
1, 2RecruitingTreatmentNeutropenias1
1, 2RecruitingTreatmentSarcomas1
1, 2TerminatedTreatmentCancer, Breast1
1, 2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1, 2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
1, 2TerminatedTreatmentCancers / Lung Cancer Small Cell Lung Cancer (SCLC)1
1, 2TerminatedTreatmentHER2 Positive Metastatic Breast Cancers1
1, 2TerminatedTreatmentHead and Neck Carcinoma1
1, 2TerminatedTreatmentLiver Cancer1
1, 2TerminatedTreatmentMale Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2TerminatedTreatmentMalignant Lymphomas1
1, 2TerminatedTreatmentNeoplasm Metastases / Neoplasms, Breast1
1, 2TerminatedTreatmentProstate Cancer1
1, 2TerminatedTreatmentRefractory Lymphomas / Relapsed Lymphomas1
1, 2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Unknown StatusTreatmentCancer, Breast2
1, 2Unknown StatusTreatmentMalignant Lymphomas1
1, 2Unknown StatusTreatmentSoft Tissue Sarcoma (STS)1
1, 2WithdrawnTreatmentCancer, Breast1
1, 2WithdrawnTreatmentCancers1
1, 2WithdrawnTreatmentLarge Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease / Primary Effusion Lymphomas1
1, 2WithdrawnTreatmentLarge-Cell Lymphoma, Diffuse / Lymphoma, Diffuse Large-Cell / Lymphoma, Diffuse Large-Cell B-cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingBasic ScienceStage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Active Not RecruitingOtherCancer, Breast / Locally Advanced Malignant Neoplasm1
2Active Not RecruitingSupportive CareLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma1
2Active Not RecruitingTreatmentAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Ph Positive Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentCD20 Positive / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
2Active Not RecruitingTreatmentCancer, Breast11
2Active Not RecruitingTreatmentCancer, Ovarian1
2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma1
2Active Not RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Ewing Sarcoma of Bone or Soft Tissue / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
2Active Not RecruitingTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
2Active Not RecruitingTreatmentFallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Peritoneal Cancer1
2Active Not RecruitingTreatmentHepatic Metastases / Metastases / Neuroendocrine Tumors1
2Active Not RecruitingTreatmentHepatocellular,Carcinoma1
2Active Not RecruitingTreatmentHodgkins Disease (HD)1
2Active Not RecruitingTreatmentInflammatory carcinoma of the breast / Male Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Active Not RecruitingTreatmentKaposi s Sarcoma (KS)1
2Active Not RecruitingTreatmentLeukaemia, Lymphoblastic / Lymphoma, Lymphoblastic1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Active Not RecruitingTreatmentLymphoma, B-Cell2
2Active Not RecruitingTreatmentLymphoma, Hodgkins5
2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2Active Not RecruitingTreatmentMalignant Fibrous Histiocytoma (MFH) of Bone / Sarcoma, Osteogenic1
2Active Not RecruitingTreatmentMalignant Lymphomas9
2Active Not RecruitingTreatmentMalignant Lymphomas / Nonneoplastic Condition1
2Active Not RecruitingTreatmentMetastatic Adult Soft Tissue Sarcoma1
2Active Not RecruitingTreatmentMetastatic Sarcoma1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
2Active Not RecruitingTreatmentNeoplasms, Breast1
2Active Not RecruitingTreatmentNeoplasms, Ovarian1
2Active Not RecruitingTreatmentOvarian Cancer Metastatic Recurrent1
2Active Not RecruitingTreatmentPrimary Mediastinal Large B Cell Lymphoma1
2Active Not RecruitingTreatmentSarcomas1
2Active Not RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2Active Not RecruitingTreatmentThyroid Cancers1
2CompletedDiagnosticMalignant Lymphomas1
2CompletedPreventionOral Mucositis / Sarcomas1
2CompletedTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)3
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Neuroblastomas / Soft Tissue Sarcoma (STS) / Wilms' tumor1
2CompletedTreatmentAcute Lymphoblastic Leukemia, Mature B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentAdenocarcinoma Of Esophagus / Adenocarcinoma of GE Junction / Adenocarcinoma of Stomach1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdrenocortical Carcinoma / Brain and Central Nervous System Tumors / Head and Neck Carcinoma / Liver Cancer / Mesothelioma, Malignant / Pheochromocytomas / Sarcomas1
2CompletedTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
2CompletedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer1
2CompletedTreatmentAdult Primary Hepatocellular Carcinoma / Advanced Adult Primary Liver Cancer / Localized Unresectable Adult Primary Liver Cancer / Recurrent Adult Primary Liver Cancer1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Metastatic Childhood Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
2CompletedTreatmentAlveolar Childhood Rhabdomyosarcoma / Embryonal Childhood Rhabdomyosarcoma / Embryonal-botryoid Childhood Rhabdomyosarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Rhabdomyosarcoma1
2CompletedTreatmentB-All / Burkitt's Lymphoma1
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentBladder Cancers2
2CompletedTreatmentBladder Cancers / Muscle-invasive Bladder Cancer1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2CompletedTreatmentBreast Cancer Invasive Nos1
2CompletedTreatmentBurkitt's Lymphoma / Burkitt'S-like Lymphoma1
2CompletedTreatmentCancer, Breast40
2CompletedTreatmentCancer, Breast / Cardiac Toxicity1
2CompletedTreatmentCancer, Breast / Cognitive/Functional Effects / Depressive State / Malnutrition / Psychosocial Effects of Cancer and Its Treatment1
2CompletedTreatmentCancer, Breast / Elderly1
2CompletedTreatmentCancer, Breast / Fevers / Neutropenias1
2CompletedTreatmentCancer, Breast / HER2-Negative Breast Cancer1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentCancer, Breast / Neoplasms Metastasis1
2CompletedTreatmentCancer, Breast / Neoplasms, Breast3
2CompletedTreatmentCancer, Breast / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentCancer, Breast / Stage I Breast Carcinoma / Stage II Breast Cancer1
2CompletedTreatmentCancer, Ovarian4
2CompletedTreatmentCancer, Ovarian / Cancers1
2CompletedTreatmentCancer, Ovarian / Extragonadal Germ Cell Tumor1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2CompletedTreatmentCancer, Ovarian / Sarcomas1
2CompletedTreatmentCancer, Ovarian / Sarcomas / Small Intestine Cancer1
2CompletedTreatmentCarcinoma, Adenoid Cystic1
2CompletedTreatmentCarcinoma, Adrenal Cortical1
2CompletedTreatmentCarcinosarcoma / Leiomyosarcomas / Mesenchymal Tumor1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric1
2CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentChildhood Renal Cell Carcinoma / Clear Cell Renal Cell Carcinoma / Clear Cell Sarcoma of the Kidney / Papillary Renal Cell Carcinoma / Rhabdoid Tumors of the Kidney (RTK) / Stage I Renal Cell Cancer / Stage I Renal Wilms Tumor / Stage II Renal Cell Cancer / Stage II Renal Wilms Tumor / Stage III Renal Cell Cancer / Stage III Renal Wilms Tumor / Stage IV Renal Cell Cancer / Stage IV Renal Wilms Tumor1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
2CompletedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2CompletedTreatmentContiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Stage I Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2CompletedTreatmentDiffuse Large Cell Lymphoma1
2CompletedTreatmentDistal Urethral Cancer / Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter / Proximal Urethral Cancer / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Urethral Cancer Associated With Invasive Bladder Cancer1
2CompletedTreatmentEarly Triple Negative Breast Cancer1
2CompletedTreatmentEndometrial Cancers2
2CompletedTreatmentEstrogen Receptor Negative / HER2/Neu Negative / Male Breast Carcinoma / Progesterone Receptor Negative / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Triple-Negative Breast Carcinoma1
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2-positive Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2CompletedTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-positive Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentEwings Sarcoma / Neuroblastomas / Non-rhabdomyosarcoma Soft Tissue Sarcomas1
2CompletedTreatmentFollicular Lymphoma (FL)1
2CompletedTreatmentHead and Neck Carcinoma1
2CompletedTreatmentHepatocellular,Carcinoma1
2CompletedTreatmentHigh Risk Urothelial Carcinoma of the Upper Urinary Tracts / Muscle Invasive Bladder Cancer1
2CompletedTreatmentHodgkins Disease (HD) / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Hodgkin Disease / Lymphoma, Hodgkins / Malignant Lymphomas1
2CompletedTreatmentHodgkins Disease (HD) / Pediatric1
2CompletedTreatmentHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)2
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphoma, AIDS Related1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentInflammatory carcinoma of the breast / Locally Advanced Breast Cancer (LABC)1
2CompletedTreatmentInflammatory carcinoma of the breast / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2CompletedTreatmentIslet Cell Adenoma / Neoplasms Metastasis / Zollinger-Ellison Syndrome1
2CompletedTreatmentLeiomyosarcomas / Uterine Neoplasms1
2CompletedTreatmentLeukemias5
2CompletedTreatmentLeukemias / Malignant Lymphomas4
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myleoma / Myelodysplastic Syndrome / Myeloproliferative Disorders1
2CompletedTreatmentLeukemias / Neutropenias / Thrombocytopenias1
2CompletedTreatmentLiver Cancer3
2CompletedTreatmentLiver Cancer / Metastatic Cancers1
2CompletedTreatmentLymphoma, B-Cell1
2CompletedTreatmentLymphoma, Hodgkins1
2CompletedTreatmentLymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2CompletedTreatmentMale Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer1
2CompletedTreatmentMalignant Lymphomas41
2CompletedTreatmentMalignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentMalignant Lymphomas / Neurotoxicity1
2CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer1
2CompletedTreatmentMalignant Neoplasm of Stomach2
2CompletedTreatmentMantle Cell Lymphoma (MCL)3
2CompletedTreatmentMetastatic Breast Cancer (MBC)4
2CompletedTreatmentMetastatic Cancers / Prostate Cancer1
2CompletedTreatmentMetastatic Cancers / Sarcomas1
2CompletedTreatmentMetastatic Osteosarcoma1
2CompletedTreatmentMetastatic Renal Cell Carcinoma1
2CompletedTreatmentMetastatic Renal Cell Carcinoma / Renal Cell Carcinoma With Sarcomatoid Features1
2CompletedTreatmentMultiple Myeloma (MM)8
2CompletedTreatmentMultiple Myeloma (MM) / Renal Insuficiency1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm3
2CompletedTreatmentNeoplasms, Breast6
2CompletedTreatmentNeoplasms, Ovarian1
2CompletedTreatmentNeuroblastomas11
2CompletedTreatmentNeurofibromatosis Type 1 / Sarcomas1
2CompletedTreatmentNeutropenias / Sarcomas1
2CompletedTreatmentNon-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentOvarian Epithelial Cancer1
2CompletedTreatmentPeritoneal Carcinomatosis1
2CompletedTreatmentProstate Cancer3
2CompletedTreatmentProstate Cancer / Thromboembolism1
2CompletedTreatmentRecurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Salivary Gland Cancer / Salivary Gland Adenoid Cystic Carcinoma / Stage III Adenoid Cystic Carcinoma of the Oral Cavity / Stage III Salivary Gland Cancer / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Salivary Gland Cancer1
2CompletedTreatmentRecurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentRelapsed Follicular Lymphoma1
2CompletedTreatmentRenal Cancers / Sarcomas1
2CompletedTreatmentRetinoblastoma1
2CompletedTreatmentSarcoma, Osteogenic2
2CompletedTreatmentSarcomas9
2CompletedTreatmentSoft Tissue Leiomyosarcoma / Uterus Leiomyosarcoma1
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2CompletedTreatmentTriple Negative Breast Cancer (TNBC)1
2CompletedTreatmentUntreated T-Cell Angioimmunoblastic Lymphoma1
2Enrolling by InvitationTreatmentMultiple Myeloma (MM)1
2Not Yet RecruitingTreatmentB Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent B Lymphoblastic Lymphoma / Recurrent T Lymphoblastic Leukemia/Lymphoma / Refractory B Lymphoblastic Lymphoma / Refractory T Lymphoblastic Lymphoma / T Acute Lymphoblastic Leukemia / T Lymphoblastic Lymphoma1
2Not Yet RecruitingTreatmentCancer, Breast1
2Not Yet RecruitingTreatmentClassical Hodgkin Lymphoma / Lymphocyte-Depleted Classical Hodgkin Lymphoma / Lymphocyte-Rich Classical Hodgkin Lymphoma / Mixed Cellularity Classical Hodgkin Lymphoma / Nodular Sclerosis Classical Hodgkin Lymphoma1
2Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
2Not Yet RecruitingTreatmentSolitary Fibrous Tumors1
2Not Yet RecruitingTreatmentStage I Hodgkin Lymphoma / Stage IA Hodgkin Lymphoma / Stage IB Hodgkin Lymphoma / Stage II Hodgkin Lymphoma / Stage IIA Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma1
2Not Yet RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
2RecruitingPreventionCancer, Breast / Tumors, Breast1
2RecruitingPreventionMultiple Myeloma (MM)1
2RecruitingSupportive CareSarcomas1
2RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Stage III AIDS-related Lymphoma / Stage IV AIDS-related Lymphoma1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2RecruitingTreatmentAcute Myelogenous Leukaemia (AML)1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Lymphoblastic Lymphoma / CD20 Positive / Philadelphia Chromosome Positive1
2RecruitingTreatmentAdult T-Cell Leukemia/Lymphoma / Anaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Angioimmunoblastic T-Cell Lymphoma / CD30-Positive Neoplastic Cells Present / Enteropathy-Associated T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage III Anaplastic Large Cell Lymphoma / Stage IV Anaplastic Large Cell Lymphoma1
2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS1
2RecruitingTreatmentAntineoplastic Combined Chemotherapy Protocols1
2RecruitingTreatmentB-cell Acute Lymphoblastic Leukemia1
2RecruitingTreatmentBRCA1 Hereditary Breast and Ovarian Cancer Syndrome1
2RecruitingTreatmentBladder Cancers1
2RecruitingTreatmentBreast Adenocarcinoma / Breast Cancer Metastatic / Breast Cancer Stage II / Breast Cancer Stage III / Estrogen Receptor- Negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2/Neu Negative / Invasive Adenocarcinoma of the Breast / Invasive Breast Carcinoma / Locally Advanced Breast Cancer (LABC) / Progesterone Receptor Negative / Progesterone Receptor Positive Tumor / Stage II Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentCancer, Breast5
2RecruitingTreatmentCancer, Breast / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage III Breast Cancer1
2RecruitingTreatmentClassical Hodgkin Lymphoma2
2RecruitingTreatmentDIPG / Glioblastomas (GBM)1
2RecruitingTreatmentEarly Primary Breast Cancer in the Elderly1
2RecruitingTreatmentEarly Stage Breast Cancer1
2RecruitingTreatmentEndometrial Clear Cell Carcinoma / Ovarian Clear Cell Carcinoma1
2RecruitingTreatmentEpithelioid Sarcoma / Fibrosarcomas malignant / Hemangiosarcoma / Leiomyosarcomas / Liposarcoma / Malignant Peripheral Nerve Sheath Tumour (MPNST) / Myxofibrosarcoma / Soft Tissue Sarcoma (STS) / Synovial Sarcoma / Undifferentiated Pleomorphic Sarcoma1
2RecruitingTreatmentEpstein Barr Virus Associated Hodgkin's Lymphoma / Epstein Barr Virus Associated Non Hodgkin's Lymphoma / Post-transplant Lymphoproliferative Disease (PTLD)1
2RecruitingTreatmentEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma1
2RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Progesterone Receptor Negative / Progesterone Receptor Positive / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / HER2-positive Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IA Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentEstrogen Receptor-negative Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentEwing's Sarcoma (ES)1
2RecruitingTreatmentExtramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2RecruitingTreatmentFallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Clear Cell Tumor / Malignant Ovarian Endometrioid Tumor / Malignant Ovarian Mixed Epithelial Tumor / Malignant Ovarian Serous Tumor / Ovarian Seromucinous Carcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
2RecruitingTreatmentFollicular Lymphoma, Grade 3b / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Transformed Lymphoma / DLBCL1
2RecruitingTreatmentGrade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Follicular Lymphoma / Refractory Follicular Lymphoma1
2RecruitingTreatmentHER-2 Positive Breast Cancer1
2RecruitingTreatmentHHV-8 / HIV Disease / Lymphoproliferative Disorders / Malignancies1
2RecruitingTreatmentHIV-associated Hodgkin Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Stage III Adult Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma1
2RecruitingTreatmentHepatocellular Cancer / Neoplasms, Hepatic1
2RecruitingTreatmentHodgkins Disease (HD)1
2RecruitingTreatmentHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast / Inflammatory carcinoma of the breast1
2RecruitingTreatmentInflammatory carcinoma of the breast1
2RecruitingTreatmentLeukemia, Lymphoblastic, Acute / Leukemias / Lymphoma, Lymphoblastic1
2RecruitingTreatmentLeukemias5
2RecruitingTreatmentLocalized Urothelial Carcinoma of the Renal Pelvis and Ureter / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter1
2RecruitingTreatmentLymphoma, Hodgkins4
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)3
2RecruitingTreatmentLymphoma, Mantle-Cell / Malignant Lymphomas1
2RecruitingTreatmentMalignant Lymphomas3
2RecruitingTreatmentMalignant Neoplasm of Breast1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentNeuroblastomas1
2RecruitingTreatmentNewly Diagnosed High Risk Neuroblastoma1
2RecruitingTreatmentNon Metastatic Disease / Soft Tissue Sarcoma (STS)1
2RecruitingTreatmentPlasma Cell Myeloma1
2RecruitingTreatmentProstate Cancer1
2RecruitingTreatmentProstatic Neoplasms1
2RecruitingTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2RecruitingTreatmentRetinoblastoma1
2RecruitingTreatmentRhabdomyosarcomas1
2RecruitingTreatmentSalivary Gland Cancers1
2RecruitingTreatmentSinonasal Tumors1
2RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2RecruitingTreatmentSoft Tissue Sarcoma, Adult / Soft Tissue Sarcoma, Child1
2RecruitingTreatmentStage I Mantle Cell Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2RecruitingTreatmentStage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2RecruitingTreatmentThyroid Gland Undifferentiated (Anaplastic) Carcinoma1
2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentUnresectable Localized Soft Tissue Sarcoma1
2RecruitingTreatmentUnresectable Sinonasal Tumors1
2RecruitingTreatmentUrothelial Carcinoma of the Bladder1
2SuspendedTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / CD30-Positive Neoplastic Cells Present / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Mixed Lineage Acute Leukemia1
2TerminatedTreatmentAnaplastic Large Cell Lymphoma1
2TerminatedTreatmentAtypical Burkitt Lymphoma / Burkitt's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentBladder Cancers3
2TerminatedTreatmentBone Cancer / Ewing's Sarcoma (ES)1
2TerminatedTreatmentBurkitt's Lymphoma / Non-Hodgkin's Lymphoma (NHL) / Primary Effusion Lymphomas1
2TerminatedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast / Tumors, Breast1
2TerminatedTreatmentCancer, Breast5
2TerminatedTreatmentCancer, Breast / Neoplasms Metastasis1
2TerminatedTreatmentCancer, Ovarian1
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2TerminatedTreatmentCardiac Toxicity / Sarcomas1
2TerminatedTreatmentCerebral Lymphoma B Cell Refractory1
2TerminatedTreatmentColon Cancer Liver Metastasis1
2TerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2TerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2TerminatedTreatmentDuctal Carcinoma1
2TerminatedTreatmentEarly-Stage Breast Cancer1
2TerminatedTreatmentEpithelial Ovarian Carcinoma1
2TerminatedTreatmentEwing's Sarcoma (ES)1
2TerminatedTreatmentFallopian Tube Cancer / Recurrent Ovarian Cancer1
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLeukemias / Lymphoma, Lymphoblastic / Malignant Lymphomas / Precursor-B Acute Lymphoblastic Leukemia1
2TerminatedTreatmentLeukemias / Malignant Lymphomas1
2TerminatedTreatmentLiver Cancer1
2TerminatedTreatmentLocally Advanced HER2-negative Breast Cancer1
2TerminatedTreatmentLung Cancers1
2TerminatedTreatmentLymphatic Diseases / Lymphoma, B-Cell1
2TerminatedTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentLymphoma, Hodgkins1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentLymphoma, Lymphoblastic1
2TerminatedTreatmentMalignant Lymphomas4
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)2
2TerminatedTreatmentMetastatic Cancers / Prostate Cancer1
2TerminatedTreatmentMultiple Myeloma (MM)3
2TerminatedTreatmentNeoplasms, Breast1
2TerminatedTreatmentNeuroblastomas1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentProstate Cancer1
2TerminatedTreatmentRecurrent Adult Soft Tissue Sarcoma / Stage I Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma1
2TerminatedTreatmentRefractory Multiple Myeloma1
2TerminatedTreatmentRefractory Nasopharyngeal Carcinoma1
2TerminatedTreatmentSarcomas4
2TerminatedTreatmentSarcomas / Soft Tissue Sarcoma (STS)1
2TerminatedTreatmentSoft Tissue Sarcoma (STS)1
2TerminatedTreatmentT-Cell Non-Hodgkin Lymphoma1
2Unknown StatusNot AvailableHepatocellular,Carcinoma1
2Unknown StatusTreatmentAutoimmune Thrombocytopenic Purpura1
2Unknown StatusTreatmentCancer, Breast10
2Unknown StatusTreatmentCancer, Breast / Stage II Breast Cancer / Stage III Breast Cancer1
2Unknown StatusTreatmentCancer, Ovarian1
2Unknown StatusTreatmentCancer, Ovarian / Sarcomas / Small Intestine Cancer1
2Unknown StatusTreatmentHER2-Negative Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Unknown StatusTreatmentHIV-associated Hodgkin Lymphoma1
2Unknown StatusTreatmentHepatocellular,Carcinoma2
2Unknown StatusTreatmentHodgkins Disease (HD)1
2Unknown StatusTreatmentLeukemia, Plasma Cell / Multiple Myeloma (MM)1
2Unknown StatusTreatmentLeukemias2
2Unknown StatusTreatmentLiver Cancer3
2Unknown StatusTreatmentLocally Advanced Soft Tissue Sarcoma / Metastatic Soft Tissue Sarcoma / Unresectable Soft Tissue Sarcoma1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentLymphoma, Mantle-Cell1
2Unknown StatusTreatmentMalignant Lymphomas10
2Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
2Unknown StatusTreatmentMesothelioma, Malignant1
2Unknown StatusTreatmentMetastatic Breast Cancer (MBC)1
2Unknown StatusTreatmentMultiple Myeloma (MM)1
2Unknown StatusTreatmentNHL With Hemophagocytic Lymphohistiocytosis1
2Unknown StatusTreatmentNeuroblastomas2
2Unknown StatusTreatmentPain / Prostate Cancer1
2Unknown StatusTreatmentPleural Mesotheliomas1
2Unknown StatusTreatmentProsthesis Survival1
2Unknown StatusTreatmentRenal Cancers2
2Unknown StatusTreatmentSoft Tissue Sarcoma (STS)2
2WithdrawnTreatmentAnterior Urethral Cancer / Localized Transitional Cell Cancer of the Renal Pelvis and Ureter / Posterior Urethral Cancer / Recurrent Bladder Cancer / Recurrent Urethral Cancer / Regional Transitional Cell Cancer of the Renal Pelvis and Ureter / Stage III Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Ureteral Cancer / Urethral Cancer Associated With Invasive Bladder Cancer1
2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2WithdrawnTreatmentCancer, Breast3
2WithdrawnTreatmentCancer, Ovarian1
2WithdrawnTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
2WithdrawnTreatmentMalignant Lymphomas3
2WithdrawnTreatmentMultiple Myeloma (MM)2
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2WithdrawnTreatmentNeoplasms, Endometrial1
2WithdrawnTreatmentRecurrent Adult Soft Tissue Sarcoma / Stage IIB Adult Soft Tissue Sarcoma / Stage IIC Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IVA Adult Soft Tissue Sarcoma1
2, 3Active Not RecruitingTreatmentCancer, Breast1
2, 3Active Not RecruitingTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma1
2, 3CompletedSupportive CareChemotherapy-Induced Neutropenia1
2, 3CompletedTreatmentHER-2 Positive Breast Cancer / Inflammatory carcinoma of breast stage IV / Inflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Malignant Neoplasm of Female Breast / Mucinous Breast Cancer Stage II / Tubular Breast Cancer Stage II / Tubular Breast Cancer Stage III1
2, 3CompletedTreatmentLymphoma, Large-Cell, Diffuse1
2, 3CompletedTreatmentMalignant Lymphomas1
2, 3RecruitingTreatmentAdult Fibrosarcoma / Alveolar Soft Part Sarcoma (ASPS) / Angiomatoid Fibrous Histiocytoma / Atypical Fibroxanthoma / Chondrosarcoma, Mesenchymal / Clear Cell Sarcoma of Soft Tissue / Epithelioid Malignant Peripheral Nerve Sheath Tumor / Epithelioid Sarcoma / Extraskeletal Myxoid Chondrosarcoma / Extraskeletal osteosarcomas / Fibrohistiocytic Neoplasm / Glomus Tumor of the Skin / Inflammatory Myofibroblastic Tumors / Intimal Sarcoma / Leiomyosarcomas / Liposarcoma / Low Grade Fibromyxoid Sarcoma / Low Grade Myofibroblastic Sarcoma / Malignant Cutaneous Granular Cell Tumor / Malignant Peripheral Nerve Sheath Tumour (MPNST) / Malignant Triton Tumor / Myxofibrosarcoma / Myxoid Chondrosarcoma / Myxoinflammatory Fibroblastic Sarcoma / Nerve Sheath Neoplasm / PEComa / Pericytic Neoplasm / Plexiform Fibrohistiocytic Tumor / Sclerosing Epithelioid Fibrosarcoma / Stage IB Soft Tissue Sarcoma / Stage IB Soft Tissue Sarcoma AJCC v7 / Stage IIB Soft Tissue Sarcoma / Stage IIB Soft Tissue Sarcoma AJCC v7 / Stage III Soft Tissue Sarcoma / Stage III Soft Tissue Sarcoma AJCC v7 / Stage IV Soft Tissue Sarcoma / Stage IV Soft Tissue Sarcoma AJCC v7 / Synovial Sarcoma / Undifferentiated (Embryonal) Sarcoma / Undifferentiated High Grade Pleomorphic Sarcoma of Bone1
2, 3RecruitingTreatmentFallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / High Grade Fallopian Tube Serous Adenocarcinoma / High Grade Ovarian Serous Adenocarcinoma / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Primary Peritoneal High Grade Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
2, 3RecruitingTreatmentLeukemias1
2, 3RecruitingTreatmentLow Grade Ovarian Serous Adenocarcinoma / Micropapillary Serous Carcinoma / Ovarian Serous Adenocarcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2, 3RecruitingTreatmentMature B-Cell Lymphoma1
2, 3RecruitingTreatmentSarcoma, Osteogenic1
2, 3SuspendedTreatmentDeleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mucinous Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Ovarian Transitional Cell Carcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
2, 3TerminatedTreatmentHepatocellular,Carcinoma1
2, 3TerminatedTreatmentMalignant Lymphomas1
2, 3TerminatedTreatmentSarcomas1
2, 3Unknown StatusNot AvailableCancer, Breast1
2, 3Unknown StatusTreatmentCancer, Breast1
2, 3Unknown StatusTreatmentSarcoma, Osteogenic1
3Active Not RecruitingNot AvailableCancer, Breast1
3Active Not RecruitingSupportive CareHematopoietic/Lymphoid Cancer / Nausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAdult Hepatocellular Carcinoma / Advanced Adult Hepatocellular Carcinoma / BCLC Stage C Adult Hepatocellular Carcinoma / BCLC Stage D Adult Hepatocellular Carcinoma / Localized Non-Resectable Adult Liver Carcinoma / Non-Resectable Hepatocellular Carcinoma / Recurrent Adult Liver Carcinoma / Recurrent Hepatocellular Carcinoma / Stage III Hepatocellular Carcinoma AJCC v7 / Stage IIIA Hepatocellular Carcinoma AJCC v7 / Stage IIIB Hepatocellular Carcinoma AJCC v7 / Stage IIIC Hepatocellular Carcinoma AJCC v7 / Stage IV Hepatocellular Carcinoma AJCC v7 / Stage IVA Hepatocellular Carcinoma AJCC v7 / Stage IVB Hepatocellular Carcinoma AJCC v71
3Active Not RecruitingTreatmentAdult Renal Wilms Tumor / Beckwith-Wiedemann Syndrome / Childhood Renal Wilms Tumor / Diffuse Hyperplastic Perilobar Nephroblastomatosis / Hemihypertrophy / Stage I Renal Wilms Tumor / Stage II Renal Wilms Tumor / Stage III Renal Wilms Tumor / Stage IV Renal Wilms Tumor / Stage V Renal Wilms Tumor1
3Active Not RecruitingTreatmentAdult Supratentorial Primitive Neuroectodermal Tumor (PNET) / Childhood Supratentorial Primitive Neuroectodermal Tumor / Ewing Sarcoma of Bone / Extraosseous Ewing Sarcoma / Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Peripheral Primitive Neuroectodermal Tumor of the Kidney / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
3Active Not RecruitingTreatmentAnaplastic Large-Cell Lymphoma / Lymphoma, Large-Cell, Anaplastic / Non-Hodgkin's Lymphoma (NHL) / T-Cell Lymphomas1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Non Hodgkin's Lymphoma / Mature B-cell Leukemia Burkitt-type1
3Active Not RecruitingTreatmentBreast Adenocarcinoma / HER2 Positive Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer1
3Active Not RecruitingTreatmentBreast Cancer Invasive Nos1
3Active Not RecruitingTreatmentCancer, Breast12
3Active Not RecruitingTreatmentCancer, Ovarian1
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentChildhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentDiffuse Large B Cell Lymphoma CD20 Positive / Diffuse Large B Cell Lymphoma CD20+1
3Active Not RecruitingTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3Active Not RecruitingTreatmentEndometrial Cancers / Recurrent Uterine Corpus Carcinoma / Stage IIIA Uterine Corpus Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Uterine Corpus Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
3Active Not RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Negative / Male Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
3Active Not RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Positive / Progesterone Receptor Negative / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIC Breast Cancer1
3Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoplasmacytic Lymphoma / Marginal Zone Lymphoma / Small Lymphocytic Lymphoma (SLL)1
3Active Not RecruitingTreatmentHepatocellular,Carcinoma1
3Active Not RecruitingTreatmentHepatocellular,Carcinoma / Non-Resectable Hepatocellular Carcinoma1
3Active Not RecruitingTreatmentHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast / Metastatic Breast Cancer (MBC)1
3Active Not RecruitingTreatmentLarge B Cell Lymphoma1
3Active Not RecruitingTreatmentLeukemias1
3Active Not RecruitingTreatmentLocalized Osteosarcoma / Metastatic Osteosarcoma1
3Active Not RecruitingTreatmentLocalized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3Active Not RecruitingTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3Active Not RecruitingTreatmentLymphoma, Hodgkins3
3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3Active Not RecruitingTreatmentLymphoma, Mantle-Cell1
3Active Not RecruitingTreatmentMalignant Lymphomas10
3Active Not RecruitingTreatmentMalignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
3Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentRecurrent Ovarian Cancer1
3Active Not RecruitingTreatmentRetinal Neoplasms / Retinoblastoma1
3Active Not RecruitingTreatmentSarcomas1
3Active Not RecruitingTreatmentSoft Tissue Sarcoma (STS)1
3Active Not RecruitingTreatmentStage I Adrenocortical Carcinoma / Stage II Adrenocortical Carcinoma / Stage III Adrenocortical Carcinoma / Stage IV Adrenocortical Carcinoma1
3Active Not RecruitingTreatmentStage I Uterine Sarcoma / Stage I Uterine Sarcoma AJCC v7 / Uterine Corpus Leiomyosarcoma1
3Active Not RecruitingTreatmentStage III Wilms Tumor With Loss of Heterozygosity (LOH) for 1p and 16q / Stage IV Wilms Tumor1
3Active Not RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
3CompletedSupportive CareCancer, Breast1
3CompletedSupportive CareCancer, Breast / Chemotherapy-Induced Neutropenia1
3CompletedSupportive CareCardiac Toxicity / Leukemias / Malignant Lymphomas1
3CompletedSupportive CareChemotherapy-Induced Neutropenia1
3CompletedTreatmentAbdominal wall neoplasm / Cancer, Ovarian / Fallopian Tube Cancer1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3CompletedTreatmentBladder Cancers2
3CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
3CompletedTreatmentBladder Cancers / Urethral Cancer1
3CompletedTreatmentCancer, Breast26
3CompletedTreatmentCancer, Breast / Cyclophosphamide / Doxorubicin / High Risk / Positive Nodes1
3CompletedTreatmentCancer, Ovarian2
3CompletedTreatmentCancer, Ovarian / Endometrial Cancers / Metastatic Cancers / Pheochromocytomas / Renal Cancers / Sarcomas1
3CompletedTreatmentCancer, Ovarian / Endometrial Cancers / Pheochromocytomas / Renal Cancers / Sarcomas1
3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer1
3CompletedTreatmentCarcinoma, Adrenal Cortical1
3CompletedTreatmentCardiac Toxicity / Malignant Lymphomas2
3CompletedTreatmentCardiac Toxicity / Sarcomas1
3CompletedTreatmentChildhood Lymphocyte-Depleted Classical Hodgkin Lymphoma / Childhood Mixed Cellularity Classical Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Classical Hodgkin Lymphoma / Malignant Lymphomas / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3CompletedTreatmentColorectal Cancers / Metastatic Cancers1
3CompletedTreatmentElderly Patients (>65 Years) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Clear Cell Adenocarcinoma / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Endometrial Serous Adenocarcinoma / Stage III Uterine Corpus Cancer1
3CompletedTreatmentEndometrial Cancers3
3CompletedTreatmentEndometrial Cancers / Psychosocial Effects of Cancer and Its Treatment1
3CompletedTreatmentHER2 Positive Breast Cancers / Inflammatory carcinoma of the breast / Invasive Ductal Breast Carcinoma / Malignant Neoplasm of Female Breast / Mucinous Breast Cancer Stage II / Tubular Breast Cancer Stage II / Tubular Breast Cancer Stage III1
3CompletedTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentHodgkins Disease (HD)1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)4
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentKaposi's Sarcoma AIDS Related1
3CompletedTreatmentLeukemias8
3CompletedTreatmentLeukemias / Malignant Lymphomas4
3CompletedTreatmentLiver Cancer2
3CompletedTreatmentLocalised High Grade Osteosarcoma of the Limbs / Sarcoma, Osteogenic1
3CompletedTreatmentLung Cancers2
3CompletedTreatmentLymphoma, Diffuse Large-Cell1
3CompletedTreatmentLymphoma, Hodgkins5
3CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
3CompletedTreatmentM-Protein / Multiple Myeloma (MM) / Myeloma Proteins / Plasma Cell Myeloma1
3CompletedTreatmentMalignant Lymphomas15
3CompletedTreatmentMetastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma1
3CompletedTreatmentMultiple Myeloma (MM)5
3CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
3CompletedTreatmentNeoplasms, Breast1
3CompletedTreatmentNeuroblastomas7
3CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentProstate Cancer2
3CompletedTreatmentRenal Cancers2
3CompletedTreatmentSarcomas7
3CompletedTreatmentSoft Tissue Sarcoma (STS)1
3CompletedTreatmentStage I Wilms Tumor / Stage II Wilms Tumor / Stage III Wilms Tumor1
3CompletedTreatmentStage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
3Not Yet RecruitingTreatmentChildhood Ganglioneuroblastoma / Childhood Neuroblastoma / NMYC Gene Amplification / Recurrent Neuroblastoma1
3Not Yet RecruitingTreatmentHepatoblastomas / Hepatocellular,Carcinoma1
3Not Yet RecruitingTreatmentLymphoma, Hodgkins1
3Not Yet RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3Not Yet RecruitingTreatmentUterine or Soft Tissue Leiomyosarcoma1
3RecruitingDiagnosticAdults With Unresectable Liver-dominant Neuroendocrine Tumor Metastases That Are Are Symptomatic, Progressive, or Involve 25% of the Liver Volume1
3RecruitingTreatmentAbdominal wall neoplasm / Fallopian Tube Neoplasms / Neoplasms, Ovarian1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3RecruitingTreatmentAdult B Lymphoblastic Lymphoma / Childhood B Acute Lymphoblastic Leukemia / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Lymphoblastic Lymphoma / Down Syndrome (DS) / Stage I B Lymphoblastic Lymphoma / Stage II B Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentBRCA Rearrangement / Deleterious BRCA1 Gene Mutation / Deleterious BRCA2 Gene Mutation / Endometrial Undifferentiated Carcinoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Transitional Cell Carcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Clear Cell Adenocarcinoma / Ovarian Endometrioid Tumor / Ovarian Seromucinous Carcinoma / Ovarian Serous Tumor / Ovarian Transitional Cell Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3RecruitingTreatmentBreast Adenocarcinoma / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIC Breast Cancer / Triple-Negative Breast Carcinoma1
3RecruitingTreatmentCancer, Breast3
3RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Ovarian Epithelial Cancer / Primary Fallopian Tube Cancer / Primary Peritoneal Carcinoma1
3RecruitingTreatmentChildhood Hodgkin Lymphoma / Classical Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
3RecruitingTreatmentClassical Hodgkin Lymphoma1
3RecruitingTreatmentEwing's Sarcoma (ES)1
3RecruitingTreatmentFollicular Lymphoma (FL)1
3RecruitingTreatmentFollicular Non-Hodgkin's Lymphoma1
3RecruitingTreatmentGanglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma1
3RecruitingTreatmentHepatocellular,Carcinoma1
3RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3RecruitingTreatmentLymphohistiocytosis, Hemophagocytic2
3RecruitingTreatmentLymphoma, Extranodal NK-T-Cell1
3RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)6
3RecruitingTreatmentMalignant Lymphomas1
3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
3RecruitingTreatmentMetastatic Ewing Sarcoma / Metastatic Malignant Neoplasm in the Bone / Metastatic Malignant Neoplasm in the Bone Marrow / Metastatic Malignant Neoplasm in the Lung / Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone / Peripheral Primitive Neuroectodermal Tumor of Soft Tissues1
3RecruitingTreatmentMultiple Myeloma (MM)2
3RecruitingTreatmentNeuroblastomas1
3RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentPRETEXT Stage 1 Hepatoblastoma / PRETEXT Stage 2 Hepatoblastoma / PRETEXT Stage 3 Hepatoblastoma / PRETEXT Stage 4 Hepatoblastoma1
3RecruitingTreatmentTriple Negative Breast Neoplasms1
3RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3SuspendedTreatmentBrain Cancer / Choroid Plexus Tumors1
3SuspendedTreatmentCancer, Breast1
3SuspendedTreatmentCancer, Ovarian1
3SuspendedTreatmentMalignant Lymphomas1
3TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedTreatmentCancer, Breast1
3TerminatedTreatmentCardiac Toxicity / Inflammatory carcinoma of the breast / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IV Breast Cancer1
3TerminatedTreatmentEndometrial Cancers2
3TerminatedTreatmentLymphoma, B Cell1
3TerminatedTreatmentMalignant Lymphomas3
3TerminatedTreatmentMetastatic Breast Cancer (MBC)1
3TerminatedTreatmentMultiple Myeloma (MM)1
3TerminatedTreatmentNeoplasms, Ovarian2
3TerminatedTreatmentOvarian Epithelial Cancer1
3TerminatedTreatmentProstate Cancer2
3TerminatedTreatmentSarcomas1
3Unknown StatusDiagnosticCancer, Breast1
3Unknown StatusSupportive CareUnspecified Adult Solid Tumor, Protocol Specific1
3Unknown StatusTreatmentAdult Alveolar Soft-part Sarcoma / Adult Angiosarcoma / Adult Epithelioid Sarcoma / Adult Extraskeletal Chondrosarcoma / Adult Extraskeletal Osteosarcoma / Adult Fibrosarcoma / Adult Leiomyosarcoma / Adult Liposarcoma / Adult Malignant Fibrous Histiocytoma / Adult Malignant Hemangiopericytoma / Adult Malignant Mesenchymoma / Adult Neurofibrosarcoma / Adult Synovial Sarcoma / Childhood Alveolar Soft-part Sarcoma / Childhood Angiosarcoma / Childhood Epithelioid Sarcoma / Childhood Fibrosarcoma / Childhood Leiomyosarcoma / Childhood Liposarcoma / Childhood Malignant Mesenchymoma / Childhood Neurofibrosarcoma / Childhood Synovial Sarcoma / Dermatofibrosarcoma Protuberans / Metastatic Childhood Soft Tissue Sarcoma / Nonmetastatic Childhood Soft Tissue Sarcoma / Stage I Adult Soft Tissue Sarcoma / Stage II Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
3Unknown StatusTreatmentBladder Cancers1
3Unknown StatusTreatmentCancer, Breast5
3Unknown StatusTreatmentCancer, Ovarian1
3Unknown StatusTreatmentCarcinoma of Unknown Primary1
3Unknown StatusTreatmentChildhood Malignant Fibrous Histiocytoma of Bone / Sarcomas1
3Unknown StatusTreatmentHepatocellular,Carcinoma1
3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
3Unknown StatusTreatmentLeukemias2
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
3Unknown StatusTreatmentLiver Cancer1
3Unknown StatusTreatmentLung Cancers2
3Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
3Unknown StatusTreatmentLymphoma, Hodgkins1
3Unknown StatusTreatmentLymphoma, Mantle-Cell1
3Unknown StatusTreatmentMalignant Lymphomas9
3Unknown StatusTreatmentMesothelioma, Malignant1
3Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm3
3Unknown StatusTreatmentNeuroblastomas2
3Unknown StatusTreatmentRenal Cancers1
3Unknown StatusTreatmentSarcomas3
3Unknown StatusTreatmentUterine Sarcoma1
3WithdrawnTreatmentHepatocellular,Carcinoma1
3WithdrawnTreatmentSarcomas1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4CompletedTreatmentAdult Acute Lymphocytic Leukemia4
4CompletedTreatmentBurkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentLocally Advanced Breast Cancer (LABC)1
4CompletedTreatmentLymphoma, Lymphoblastic1
4CompletedTreatmentNeoplasms, Breast1
4CompletedTreatmentNeoplasms, Ovarian1
4CompletedTreatmentNon Burkitt / Post-transplant Lymphoproliferative Disease (PTLD)1
4CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
4RecruitingNot AvailableBMI >30 kg/m2 / Cancer, Breast1
4RecruitingPreventionCarcinoma of Urinary Bladder, Superficial1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4RecruitingTreatmentCancer, Breast1
4RecruitingTreatmentMantle Cell Lymphoma (MCL)1
4RecruitingTreatmentMultiple Myeloma (MM)1
4TerminatedTreatmentNeoplasms, Breast1
4Unknown StatusNot AvailableRhabdomyosarcomas1
4Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL) / Non-Hodgkin's Lymphoma (NHL)1
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia1
Not AvailableActive Not RecruitingNot AvailableCancer, Breast1
Not AvailableActive Not RecruitingNot AvailableCancer, Breast / Chemotherapeutic Agent Toxicity / Cognitive/Functional Effects / Long-Term Effects Secondary to Cancer Therapy in Adults / Neurotoxicity / Psychosocial Effects of Cancer and Its Treatment / Tiredness1
Not AvailableActive Not RecruitingDiagnosticSarcomas1
Not AvailableActive Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableActive Not RecruitingTreatmentCancer, Breast2
Not AvailableActive Not RecruitingTreatmentCancer, Breast / Pregnancy1
Not AvailableActive Not RecruitingTreatmentChildhood Lymphocyte Predominant Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
Not AvailableActive Not RecruitingTreatmentLeukemias1
Not AvailableActive Not RecruitingTreatmentStage IIA Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
Not AvailableCompletedNot AvailableCancer, Breast1
Not AvailableCompletedNot AvailableCancer, Breast / Metastatic Cancers1
Not AvailableCompletedNot AvailableLymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma1
Not AvailableCompletedNot AvailableNeoplasms, Ovarian1
Not AvailableCompletedNot AvailableSarcoma, Osteogenic / Spindle Cell Sarcoma of Bone1
Not AvailableCompletedDiagnosticDoxorubicin Induced Cardiomyopathy / Malignant Neoplasm of Female Breast1
Not AvailableCompletedPreventionSarcomas1
Not AvailableCompletedSupportive CareMale Breast Cancer / Nausea and Vomiting / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer1
Not AvailableCompletedSupportive CareMultiple Myeloma (MM)1
Not AvailableCompletedSupportive CareNausea / Sarcomas / Vomiting1
Not AvailableCompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T-Cell Leukemia/Lymphoma / Burkitt's Lymphoma / Lymphoid Malignancies (New or Relapsed) / Lymphoma, Lymphoblastic / Mantle Cell Lymphoma (MCL)1
Not AvailableCompletedTreatmentAdverse Effects of Medical Drugs / Effects of Chemotherapy / Prophylaxis of acute chemotherapy induced nausea and vomiting / Sarcomas1
Not AvailableCompletedTreatmentAtaxia-Telangiectasia1
Not AvailableCompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentCancer, Breast5
Not AvailableCompletedTreatmentCancer, Ovarian / Sarcomas1
Not AvailableCompletedTreatmentDisseminated Neuroblastoma / Ganglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableCompletedTreatmentEwing Sarcoma of Bone / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentL1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Non-T, Non-B Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Post Transplant Lymphoproliferative Disorder / Primary Mediastinal (Thymic) Large B-cell Lymphoma1
Not AvailableCompletedTreatmentLymphoma, Large Cell / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentMalignant Lymphomas2
Not AvailableCompletedTreatmentMultiple Myeloma (MM)1
Not AvailableCompletedTreatmentSarcomas1
Not AvailableCompletedTreatmentT-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableRecruitingNot AvailableCancer, Breast1
Not AvailableRecruitingNot AvailableCholangiocarcinomas1
Not AvailableRecruitingHealth Services ResearchCancer, Breast1
Not AvailableRecruitingTreatmentAIDS Related Non-Hodgkin Lymphoma / AIDS-Related Burkitt Lymphoma / AIDS-Related Diffuse Large B-cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableRecruitingTreatmentCervical Cancers / Uterine Cancers1
Not AvailableRecruitingTreatmentClassical Hodgkins Lymphoma in Children and Adolescents1
Not AvailableRecruitingTreatmentComposite Lymphoma / Grade 3b Follicular Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage I Follicular Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Follicular Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage III Follicular Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Follicular Lymphoma1
Not AvailableRecruitingTreatmentLiver Cancer1
Not AvailableRecruitingTreatmentLymphoma, Hodgkins1
Not AvailableRecruitingTreatmentNeuroblastomas2
Not AvailableRecruitingTreatmentPleuropulmonary Blastoma1
Not AvailableRecruitingTreatmentRecurrent Fallopian Tube Cancer / Recurrent Ovarian Cancer / Recurrent Primary Peritoneal Cancer / Recurrent Uterine Corpus Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIA Uterine Corpus Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIB Uterine Corpus Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IIIC Uterine Corpus Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cavity Cancer / Stage IVA Uterine Corpus Cancer / Stage IVB Uterine Corpus Cancer1
Not AvailableRecruitingTreatmentStage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
Not AvailableSuspendedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableTerminatedNot AvailableCancer, Breast1
Not AvailableTerminatedTreatmentCancer, Ovarian1
Not AvailableTerminatedTreatmentContiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma1
Not AvailableTerminatedTreatmentSarcoma, Osteogenic1
Not AvailableTerminatedTreatmentT-Cell Lymphomas1
Not AvailableUnknown StatusNot AvailableCancer, Breast / Cardiac Toxicity / Cardiovascular Complications1
Not AvailableUnknown StatusDiagnosticCardiac Toxicity / Chemotherapeutic Agent Toxicity / Malignant Lymphomas1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1
Not AvailableUnknown StatusTreatmentCancer, Breast3
Not AvailableUnknown StatusTreatmentChemotherapy, Adjuvant / Hepatocellular,Carcinoma / Survival / Transplantation, Liver / Tumor Recurrence and Metastasis1
Not AvailableUnknown StatusTreatmentLeukemias1
Not AvailableUnknown StatusTreatmentMalignant Lymphomas2
Not AvailableWithdrawnDiagnosticMalignant Lymphomas1
Not AvailableWithdrawnTreatmentCancer, Breast2
Not AvailableWithdrawnTreatmentHepatocellular,Carcinoma2
Not AvailableWithdrawnTreatmentMalignant Lymphomas1
Pharmacoeconomics
Manufacturers
  • Ortho biotech products lp
  • Pharmacia and upjohn co
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Pharmachemie bv
  • Teva parenteral medicines inc
  • Bristol myers squibb co
Packagers
Dosage forms
FormRouteStrength
SolutionIntravenous; Intravesical2 mg
Injection, solution, concentrateIntravenous2 mg/ml
SuspensionIntravenous2 mg
Injection, suspension, liposomalIntravenous2 mg/mL
Powder, for solutionIntravenous10 mg
Powder, for solutionIntravenous150 mg
Powder, for solutionIntravenous50 mg
Injectable, liposomalIntravenous2 mg/mL
InjectionIntravenous10 mg/5mL
InjectionIntravenous20 mg/10mL
InjectionIntravenous200 mg/100mL
InjectionIntravenous50 mg/25mL
Injection, powder, lyophilized, for solutionIntravenous2 mg/mL
Injection, solutionIntravenous2 mg/mL
SolutionIntravenous2 mg
Injectable, liposomalIntravenous2 mg
Injection, powder, for solutionIntravenous50 mg
Prices
Unit descriptionCostUnit
Doxorubicin 50 mg vial132.0USD vial
Doxil 2 mg/ml vial115.78USD ml
Adriamycin 50 mg vial64.8USD vial
Doxorubicin 10 mg vial44.4USD vial
Adriamycin 20 mg vial26.4USD vial
Adriamycin 10 mg vial13.2USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5013556 No1992-10-202009-10-20Us
CA1338702 No1998-11-122013-11-12Canada
CA1335565 No1995-05-162012-05-16Canada
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)229-231 °CPhysProp
water solubilitySolubleNot Available
logP1.27HANSCH,C ET AL. (1995)
Caco2 permeability-6.8ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility1.18 mg/mLALOGPS
logP1.41ALOGPS
logP0.92ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)9.53ChemAxon
pKa (Strongest Basic)8.94ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area206.07 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity134.59 m3·mol-1ChemAxon
Polarizability53.87 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8092
Blood Brain Barrier-0.9951
Caco-2 permeable-0.799
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.9053
CYP450 2C9 substrateNon-substrate0.8042
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5888
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9209
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8911
Ames testAMES toxic0.9198
CarcinogenicityNon-carcinogens0.9534
BiodegradationNot ready biodegradable0.9672
Rat acute toxicity2.6644 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9752
hERG inhibition (predictor II)Non-inhibitor0.7195
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-qTof , PositiveNot Available
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-006t-0109000000-ac65f689e3fa439adddcView in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassAnthracyclines
Sub ClassNot Available
Direct ParentAnthracyclines
Alternative ParentsTetracenequinones / Aminoglycosides / Anthraquinones / Hexoses / O-glycosyl compounds / Tetralins / Anisoles / Aryl ketones / Alkyl aryl ethers / Oxanes
SubstituentsAnthracycline / Anthracyclinone-skeleton / Aminoglycoside core / Tetracenequinone / 9,10-anthraquinone / 1,4-anthraquinone / Anthracene / Hexose monosaccharide / Glycosyl compound / O-glycosyl compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorsquinone, anthracycline antibiotic, aminoglycoside, deoxy hexoside, anthracycline (CHEBI:28748 ) / Other Polyketides, Anthracyclinones (C01661 ) / Anthracyclinones (LMPK13050001 )

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
intercalation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA: Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994 Apr;45(4):649-56. [PubMed:8183243 ]
  2. Momparler RL, Karon M, Siegel SE, Avila F: Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 1976 Aug;36(8):2891-5. [PubMed:1277199 ]
  3. Frederick CA, Williams LD, Ughetto G, van der Marel GA, van Boom JH, Rich A, Wang AH: Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry. 1990 Mar 13;29(10):2538-49. [PubMed:2334681 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Uniprot Name:
DNA topoisomerase 2-alpha
Molecular Weight:
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Rody A, Karn T, Gatje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhaberle E, Holtrich U, von Minckwitz G, Kaufmann M: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast. 2007 Feb;16(1):86-93. Epub 2006 Sep 28. [PubMed:17010609 ]
  3. Koehn H, Magan N, Isaacs RJ, Stowell KM: Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin. Anticancer Drugs. 2007 Apr;18(4):419-25. [PubMed:17351394 ]
  4. Hayashi S, Hatashita M, Matsumoto H, Shioura H, Kitai R, Kano E: Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction. Int J Mol Med. 2006 Nov;18(5):909-15. [PubMed:17016621 ]
  5. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, Liu LF: Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11014-9. Epub 2007 Jun 19. [PubMed:17578914 ]
  6. Menendez JA, Vellon L, Lupu R: DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes. Int J Mol Med. 2006 Dec;18(6):1081-7. [PubMed:17089011 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Poly(a) rna binding
Specific Function:
Related to nucleologenesis, may play a role in the maintenance of the fundamental structure of the fibrillar center and dense fibrillar component in the nucleolus. It has intrinsic GTPase and ATPase activities. May play an important role in transcription catalyzed by RNA polymerase I.
Gene Name:
NOLC1
Uniprot ID:
Q14978
Uniprot Name:
Nucleolar and coiled-body phosphoprotein 1
Molecular Weight:
73602.49 Da
References
  1. Kim YK, Lee WK, Jin Y, Lee KJ, Jeon H, Yu YG: Doxorubicin binds to un-phosphorylated form of hNopp140 and reduces protein kinase CK2-dependent phosphorylation of hNopp140. J Biochem Mol Biol. 2006 Nov 30;39(6):774-81. [PubMed:17129415 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Lu H, Chen CS, Waxman DJ: Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer. Cancer Gene Ther. 2009 May;16(5):393-404. doi: 10.1038/cgt.2008.93. Epub 2008 Nov 14. [PubMed:19011599 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Uniprot Name:
Cytochrome P450 2B6
Molecular Weight:
56277.81 Da
References
  1. Masek V, Anzenbacherova E, Etrych T, Strohalm J, Ulbrich K, Anzenbacher P: Interaction of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates with human liver microsomal cytochromes P450: comparison with free doxorubicin. Drug Metab Dispos. 2011 Sep;39(9):1704-10. doi: 10.1124/dmd.110.037986. Epub 2011 Jun 3. [PubMed:21642392 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Uniprot Name:
Cytochrome P450 2D6
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Uniprot Name:
Cytochrome P450 1B1
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-e2 9-reductase activity
Specific Function:
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alp...
Gene Name:
CBR1
Uniprot ID:
P16152
Uniprot Name:
Carbonyl reductase [NADPH] 1
Molecular Weight:
30374.73 Da
References
  1. Kassner N, Huse K, Martin HJ, Godtel-Armbrust U, Metzger A, Meineke I, Brockmoller J, Klein K, Zanger UM, Maser E, Wojnowski L: Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20. doi: 10.1124/dmd.108.022251. Epub 2008 Jul 17. [PubMed:18635746 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Nadph binding
Specific Function:
Has low NADPH-dependent oxidoreductase activity towards 4-benzoylpyridine and menadione (in vitro).
Gene Name:
CBR3
Uniprot ID:
O75828
Uniprot Name:
Carbonyl reductase [NADPH] 3
Molecular Weight:
30849.97 Da
References
  1. Bains OS, Karkling MJ, Lubieniecka JM, Grigliatti TA, Reid RE, Riggs KW: Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther. 2010 Mar;332(3):755-63. doi: 10.1124/jpet.109.160614. Epub 2009 Dec 9. [PubMed:20007405 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
L-glucuronate reductase activity
Specific Function:
Catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic aldehydes to their corresponding alcohols. Catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyde to glycerol. Has broad substrate specificity. In vitro substrates include succinic semialdehyde, 4-nitrobenzaldehyde, 1,2-naphthoquinone, methylglyoxal, and D-glucuronic acid. Plays a role in the ac...
Gene Name:
AKR1A1
Uniprot ID:
P14550
Uniprot Name:
Alcohol dehydrogenase [NADP(+)]
Molecular Weight:
36572.71 Da
References
  1. Kassner N, Huse K, Martin HJ, Godtel-Armbrust U, Metzger A, Meineke I, Brockmoller J, Klein K, Zanger UM, Maser E, Wojnowski L: Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20. doi: 10.1124/dmd.108.022251. Epub 2008 Jul 17. [PubMed:18635746 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity
Specific Function:
Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms andro...
Gene Name:
AKR1C3
Uniprot ID:
P42330
Uniprot Name:
Aldo-keto reductase family 1 member C3
Molecular Weight:
36852.89 Da
References
  1. Novotna R, Wsol V, Xiong G, Maser E: Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6. doi: 10.1016/j.toxlet.2008.06.858. Epub 2008 Jun 21. [PubMed:18616992 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Superoxide dismutase activity
Specific Function:
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinons involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.
Gene Name:
NQO1
Uniprot ID:
P15559
Uniprot Name:
NAD(P)H dehydrogenase [quinone] 1
Molecular Weight:
30867.405 Da
References
  1. Pawlowska J, Tarasiuk J, Wolf CR, Paine MJ, Borowski E: Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. [PubMed:12688675 ]
  2. Niitsu N, Kasukabe T, Yokoyama A, Okabe-Kado J, Yamamoto-Yamaguchi Y, Umeda M, Honma Y: Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Mol Pharmacol. 2000 Jul;58(1):27-36. [PubMed:10860924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xanthine oxidase activity
Specific Function:
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro).
Gene Name:
XDH
Uniprot ID:
P47989
Uniprot Name:
Xanthine dehydrogenase/oxidase
Molecular Weight:
146422.99 Da
References
  1. Pawlowska J, Tarasiuk J, Wolf CR, Paine MJ, Borowski E: Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. [PubMed:12688675 ]
  2. Niitsu N, Kasukabe T, Yokoyama A, Okabe-Kado J, Yamamoto-Yamaguchi Y, Umeda M, Honma Y: Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Mol Pharmacol. 2000 Jul;58(1):27-36. [PubMed:10860924 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Tetrahydrobiopterin binding
Specific Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. Probably has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such SRR.
Gene Name:
NOS1
Uniprot ID:
P29475
Uniprot Name:
Nitric oxide synthase, brain
Molecular Weight:
160969.095 Da
References
  1. Vasquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA Jr, Kalyanaraman B: Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 1997 Sep 23;36(38):11293-7. [PubMed:9333325 ]
  2. Fogli S, Nieri P, Breschi MC: The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75. [PubMed:15054088 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Tetrahydrobiopterin binding
Specific Function:
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such COX2. As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-n...
Gene Name:
NOS2
Uniprot ID:
P35228
Uniprot Name:
Nitric oxide synthase, inducible
Molecular Weight:
131116.3 Da
References
  1. Vasquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA Jr, Kalyanaraman B: Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 1997 Sep 23;36(38):11293-7. [PubMed:9333325 ]
  2. Fogli S, Nieri P, Breschi MC: The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75. [PubMed:15054088 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Tetrahydrobiopterin binding
Specific Function:
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets.Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by ...
Gene Name:
NOS3
Uniprot ID:
P29474
Uniprot Name:
Nitric oxide synthase, endothelial
Molecular Weight:
133287.62 Da
References
  1. Vasquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA Jr, Kalyanaraman B: Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 1997 Sep 23;36(38):11293-7. [PubMed:9333325 ]
  2. Fogli S, Nieri P, Breschi MC: The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75. [PubMed:15054088 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Ubiquitin protein ligase binding
Specific Function:
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).
Gene Name:
NDUFS2
Uniprot ID:
O75306
Uniprot Name:
NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial
Molecular Weight:
52545.26 Da
References
  1. Pawlowska J, Tarasiuk J, Wolf CR, Paine MJ, Borowski E: Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. [PubMed:12688675 ]
  2. Thornalley PJ, Bannister WH, Bannister JV: Reduction of oxygen by NADH/NADH dehydrogenase in the presence of adriamycin. Free Radic Res Commun. 1986;2(3):163-71. [PubMed:2850270 ]
  3. Nohl H, Gille L, Staniek K: The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch C. 1998 Mar-Apr;53(3-4):279-85. [PubMed:9618942 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Nadh dehydrogenase activity
Specific Function:
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).
Gene Name:
NDUFS3
Uniprot ID:
O75489
Uniprot Name:
NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial
Molecular Weight:
30241.245 Da
References
  1. Pawlowska J, Tarasiuk J, Wolf CR, Paine MJ, Borowski E: Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. [PubMed:12688675 ]
  2. Thornalley PJ, Bannister WH, Bannister JV: Reduction of oxygen by NADH/NADH dehydrogenase in the presence of adriamycin. Free Radic Res Commun. 1986;2(3):163-71. [PubMed:2850270 ]
  3. Nohl H, Gille L, Staniek K: The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch C. 1998 Mar-Apr;53(3-4):279-85. [PubMed:9618942 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Quinone binding
Specific Function:
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).
Gene Name:
NDUFS7
Uniprot ID:
O75251
Uniprot Name:
NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrial
Molecular Weight:
23563.3 Da
References
  1. Pawlowska J, Tarasiuk J, Wolf CR, Paine MJ, Borowski E: Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. [PubMed:12688675 ]
  2. Thornalley PJ, Bannister WH, Bannister JV: Reduction of oxygen by NADH/NADH dehydrogenase in the presence of adriamycin. Free Radic Res Commun. 1986;2(3):163-71. [PubMed:2850270 ]
  3. Nohl H, Gille L, Staniek K: The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch C. 1998 Mar-Apr;53(3-4):279-85. [PubMed:9618942 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
This enzyme is required for electron transfer from NADP to cytochrome P450 in microsomes. It can also provide electron transfer to heme oxygenase and cytochrome B5.
Gene Name:
POR
Uniprot ID:
P16435
Uniprot Name:
NADPH--cytochrome P450 reductase
Molecular Weight:
76689.12 Da
References
  1. Gutierrez PL, Gee MV, Bachur NR: Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75. [PubMed:6305277 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Uniprot Name:
Serum albumin
Molecular Weight:
69365.94 Da
References
  1. Kratz F, Mansour A, Soltau J, Warnecke A, Fichtner I, Unger C, Drevs J: Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. Arch Pharm (Weinheim). 2005 Oct;338(10):462-72. [PubMed:16211657 ]
  2. Schmid B, Chung DE, Warnecke A, Fichtner I, Kratz F: Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem. 2007 May-Jun;18(3):702-16. Epub 2007 Mar 23. [PubMed:17378599 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Uniprot Name:
Multidrug resistance protein 1
Molecular Weight:
141477.255 Da
References
  1. Fardel O, Lecureur V, Daval S, Corlu A, Guillouzo A: Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem. 1997 May 15;246(1):186-92. [PubMed:9210482 ]
  2. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287 ]
  3. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K: Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999 Dec;22(12):1355-9. [PubMed:10746169 ]
  4. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. doi: 10.1016/j.phrs.2009.07.002. Epub 2009 Jul 21. [PubMed:19631272 ]
  5. Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50. [PubMed:12608535 ]
  6. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  7. Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ: In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides. 2003 Jul;24(7):945-53. [PubMed:14499271 ]
  8. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I: Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8472-6. [PubMed:1356264 ]
  9. Kusunoki N, Takara K, Tanigawara Y, Yamauchi A, Ueda K, Komada F, Ku Y, Kuroda Y, Saitoh Y, Okumura K: Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res. 1998 Nov;89(11):1220-8. [PubMed:9914792 ]
  10. Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, Kong SK: Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. Chemotherapy. 2004 Jun;50(2):55-62. [PubMed:15211078 ]
  11. Sieczkowski E, Lehner C, Ambros PF, Hohenegger M: Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010 May 1;126(9):2025-35. doi: 10.1002/ijc.24885. [PubMed:19739078 ]
  12. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV: Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9. doi: 10.1038/sj.bjc.6605587. Epub 2010 Feb 23. [PubMed:20179710 ]
  13. Tao LY, Liang YJ, Wang F, Chen LM, Yan YY, Dai CL, Fu LW: Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol. 2009 Oct;64(5):961-9. doi: 10.1007/s00280-009-0949-1. Epub 2009 Mar 3. [PubMed:19255759 ]
  14. Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. doi: 10.1007/s00280-008-0906-4. Epub 2009 Jan 4. [PubMed:19123050 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Uniprot Name:
Multidrug resistance-associated protein 1
Molecular Weight:
171589.5 Da
References
  1. Loe DW, Almquist KC, Cole SP, Deeley RG: ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem. 1996 Apr 19;271(16):9683-9. [PubMed:8621644 ]
  2. Godinot N, Iversen PW, Tabas L, Xia X, Williams DC, Dantzig AH, Perry WL 3rd: Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey. Mol Cancer Ther. 2003 Mar;2(3):307-16. [PubMed:12657726 ]
  3. Tribull TE, Bruner RH, Bain LJ: The multidrug resistance-associated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. Toxicol Lett. 2003 Apr 30;142(1-2):61-70. [PubMed:12765240 ]
  4. Nunoya K, Grant CE, Zhang D, Cole SP, Deeley RG: Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1). Drug Metab Dispos. 2003 Aug;31(8):1016-26. [PubMed:12867490 ]
  5. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SP, Deeley RG: Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997 Sep;52(3):344-53. [PubMed:9281595 ]
  6. Wong IL, Chan KF, Tsang KH, Lam CY, Zhao Y, Chan TH, Chow LM: Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives. J Med Chem. 2009 Sep 10;52(17):5311-22. doi: 10.1021/jm900194w. [PubMed:19725578 ]
  7. Tao LY, Liang YJ, Wang F, Chen LM, Yan YY, Dai CL, Fu LW: Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol. 2009 Oct;64(5):961-9. doi: 10.1007/s00280-009-0949-1. Epub 2009 Mar 3. [PubMed:19255759 ]
  8. Zheng LS, Wang F, Li YH, Zhang X, Chen LM, Liang YJ, Dai CL, Yan YY, Tao LY, Mi YJ, Yang AK, To KK, Fu LW: Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One. 2009;4(4):e5172. doi: 10.1371/journal.pone.0005172. Epub 2009 Apr 23. [PubMed:19390592 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Uniprot Name:
Canalicular multispecific organic anion transporter 2
Molecular Weight:
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Transporter activity
Specific Function:
Isoform 1: May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. Transports glutathione conjugates as leukotriene-c4 (LTC4) and N-ethylmaleimide S-glutathione (NEM-GS).Isoform 2: Inhibits TNF-alpha-mediated apoptosis through blocking one or more caspases.
Gene Name:
ABCC6
Uniprot ID:
O95255
Uniprot Name:
Multidrug resistance-associated protein 6
Molecular Weight:
164904.81 Da
References
  1. Cai J, Daoud R, Alqawi O, Georges E, Pelletier J, Gros P: Nucleotide binding and nucleotide hydrolysis properties of the ABC transporter MRP6 (ABCC6). Biochemistry. 2002 Jun 25;41(25):8058-67. [PubMed:12069597 ]
  2. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD: Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7. [PubMed:12414644 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Uniprot Name:
ATP-binding cassette sub-family G member 2
Molecular Weight:
72313.47 Da
References
  1. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043 ]
  2. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72. [PubMed:12488537 ]
  3. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B: Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7. [PubMed:11437380 ]
  4. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44. [PubMed:12649196 ]
  5. An Y, Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1529-42. doi: 10.1517/17425250903228834. [PubMed:19708828 ]
  6. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995 ]
  7. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW: Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18. [PubMed:19232821 ]
  8. Zheng LS, Wang F, Li YH, Zhang X, Chen LM, Liang YJ, Dai CL, Yan YY, Tao LY, Mi YJ, Yang AK, To KK, Fu LW: Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One. 2009;4(4):e5172. doi: 10.1371/journal.pone.0005172. Epub 2009 Apr 23. [PubMed:19390592 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic cation transmembrane transporter activity
Specific Function:
High affinity carnitine transporter; the uptake is partially sodium-ion dependent. Thought to mediate the L-carnitine secretion mechanism from testis epididymal epithelium into the lumen which is involved in the maturation of spermatozoa. Also transports organic cations such as tetraethylammonium (TEA) and doxorubicin. The uptake of TEA is inhibited by various organic cations. The uptake of dox...
Gene Name:
SLC22A16
Uniprot ID:
Q86VW1
Uniprot Name:
Solute carrier family 22 member 16
Molecular Weight:
64613.58 Da
References
  1. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV: Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9. doi: 10.1038/sj.bjc.6605587. Epub 2010 Feb 23. [PubMed:20179710 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Uniprot Name:
Multidrug resistance-associated protein 7
Molecular Weight:
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Not Available
Gene Name:
ABCB8
Uniprot ID:
Q9NUT2
Uniprot Name:
ATP-binding cassette sub-family B member 8, mitochondrial
Molecular Weight:
79988.17 Da
References
  1. Elliott AM, Al-Hajj MA: ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res. 2009 Jan;7(1):79-87. doi: 10.1158/1541-7786.MCR-08-0235. [PubMed:19147539 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Uniprot Name:
Bile salt export pump
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transmembrane transporter activity
Specific Function:
Can activate specifically hydrolysis of GTP bound to RAC1 and CDC42, but not RALA. Mediates ATP-dependent transport of S-(2,4-dinitrophenyl)-glutathione (DNP-SG) and doxorubicin (DOX) and is the major ATP-dependent transporter of glutathione conjugates of electrophiles (GS-E) and DOX in erythrocytes. Can catalyze transport of glutathione conjugates and xenobiotics, and may contribute to the mul...
Gene Name:
RALBP1
Uniprot ID:
Q15311
Uniprot Name:
RalA-binding protein 1
Molecular Weight:
76062.86 Da
References
  1. Singhal SS, Singhal J, Nair MP, Lacko AG, Awasthi YC, Awasthi S: Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25. [PubMed:17273774 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Uniprot Name:
Canalicular multispecific organic anion transporter 1
Molecular Weight:
174205.64 Da
References
  1. Folmer Y, Schneider M, Blum HE, Hafkemeyer P: Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther. 2007 Nov;14(11):875-84. Epub 2007 Aug 17. [PubMed:17704753 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 15:53